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Foreword
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has great
pleasure in presenting its sixth General report of activities to the European Parliament,
the Council of the European Union, the European Commission and the Member
States, following its adoption by the Centre’s Management Board on 12 January 2001.
The report provides a retrospective account of the EMCDDA’s activities and
accomplishments in 2000 at the conclusion of its second three-year work pro-
gramme (1998–2000) and six years after its establishment in Lisbon.
The year 2000 was a special year for the Centre in which evaluation and future plan-
ning were at the forefront. In January, the results of an evaluation of the agency by pri-
vate consultants in 1999 were examined and, in March, the Management Board put
measures in place to address the issues raised. Recognising the need for medium-term
planning for the further development of the EMCDDA, the Board set up two working
parties on medium-term perspectives and on enlargement. It also requested the Direc-
tor to present concrete proposals for the internal reform of the Centre. The medium-
term perspectives document and the internal reform plan were presented to the Man-
agement Board in September 2000 and given the green light for implementation.
A significant political landmark in 2000 was the endorsement of the new EU action
plan on drugs (2000–04) at the European Summit of Santa Maria da Feira in June. The
action plan cites information and evaluation as preconditions for effective implemen-
tation, follow-up and assessment of EU and Member States’ drug strategies and
thereby confirms the importance of the work being carried out by the EMCDDA. It
also urges Member States, in cooperation with the EMCDDA, to enhance their efforts
to provide reliable and comparable information on key epidemiological indicators.
The follow-up to the external evaluation and the targets set out in the EU action
plan are basic principles underlying the EMCDDA’s 2001–03 work programme.
I now hand over the chair of the Management Board to the UK member, Mike Trace,
after three years of chairmanship and three years of vice-chairmanship. I would like to
express my heartfelt thanks to the colleagues on the Management Board and the
Bureau, the Director and staff of the Centre as well as the national focal point staff and
members of the Scientific Committee who have supported me over the years. The last
three years, with the evaluation and internal reform, have been demanding and a high
level of commitment was necessary to prepare the EMCDDA for its future tasks. I am
confident that on the basis of the work undertaken in the context of the reform, the
EMCDDA will be able to rise to these challenges and wish it every success.
Franz J. Bindert
Chairman of the EMCDDA Management Board
January 2001
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Introduction
Activity in 2000 concentrated on completing the EMCDDA’s second three-year
work programme (1998–2000). Alongside this, the EMCDDA staff worked inten-
sively on taking stock of the agency’s progress to date and on shaping its future
direction. Important drug-policy developments during the course of the year also
had a direct impact on the agency’s remit and activities.
Before moving on, I would like to spend a few moments remembering our dear col-
league, Roger Lewis, who tragically passed away in April and whose sudden loss
came as a shock to us all. Roger joined the EMCDDA on 1 July 1998 as Head of the
Reitox Coordination Department and was a cherished member of our team. We will
fondly remember him for his humanity and exuberance as well as his generosity and
very special brand of humour and expression. The results of his valuable work in set-
ting the Reitox network on a secure footing are much in evidence today. Posthu-
mously he was awarded the United Nations Vienna Civil Society Award in Decem-
ber in recognition of his contribution to the drugs field and to civil society in general.
The results of the external evaluation of the agency were delivered in January 2000
and made specific recommendations for the improvement of the Centre’s organisa-
tion, working methods and outputs. The EMCDDA Management Board met in
March 2000 and decided on the follow-up action to be taken in the light of these
proposals. This included setting up two working parties — one to consider the
medium-term perspectives and objectives of the EMCDDA and the Reitox network,
and one to consider an enlargement strategy for the future participation of the can-
didate countries in the Centre’s activities. Other immediate actions to be under-
taken were: developing new rules of procedure for the Management Board and a
new working framework for the Scientific Committee; defining an improvement
strategy for the Reitox network; and drawing up an internal reform plan.
The reform plan, put together after much internal reflection and discussion, defines
radical changes in the Centre’s working methods. These changes include project-
based planning and activity-based budgeting and management, and an improved
approach to quality management. This plan was approved by the Management
Board in September and will be implemented in 2001.
Besides this, new responsibilities were conferred to the agency as a consequence of
developments in EU drugs policy. The EU action plan on drugs, which transposes
the EU drugs strategy (2000–04) into concrete action, was endorsed at the European
Council of Santa Maria da Feira in June. Now that information and evaluation have
been recognised in the plan as a key to success, the agency faces the challenge of
providing policy-makers with instruments to measure the impact of action on the
drug phenomenon as well as a solid knowledge base for informed drug-policy plan-
ning. The plan also paves the way for Member States to adopt and implement each
of the EMCDDA’s five key epidemiological indicators which will enable countries to
measure the extent and effects of drug use in a harmonised way.
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Considerable effort was expended during the year in drawing all the above ele-
ments together in a draft triennial work programme (2001–03). This reflects the
new priorities of the action plan and takes into account the new structure and
working methods of the agency. The new work programme is structured around
four key aspects: monitoring the drug phenomenon in the EU; monitoring
responses to the drug phenomenon; implementing the 1997 joint action on new
synthetic drugs; and preparing tools for policy assessment and evaluation.
The agency’s target groups were redefined in the course of the year — policy-mak-
ers are now designated as the primary audience for the findings and outputs of the
agency. As a result, the agency drew up a new communication and dissemination
strategy that will ensure that their information needs are served.
The agency’s Annual report on the state of the drugs problem in the European
Union is now a well-recognised reference tool in the drugs field. In 2000, special
effort was made to distil the findings into a more concise report better suited to its
target audience. The launch, held in Brussels at the Spokesman’s Service of the
European Commission was a great success. It was also a pleasure to be able to
make a special presentation of the report to the European Parliament’s Committee
on Citizens’ Freedoms and Rights, Justice and Home Affairs, prior to its official
launch and also to present to the Committee the EMCDDA reform plan and
medium-term perspectives which were positively received.
The Reitox network, as ever, played a crucial role in the agency’s work in 2000 via
the execution of a number of ‘core tasks’ and special projects. Progress was
achieved on a two-way discussion process and the exchange of information
between the Centre and the network, as well as on the further involvement of the
Reitox focal points in general EMCDDA work programming. Work focused on the
qualitative aspects of data and reporting and a more structured system was set in
place with common criteria and a clear feedback mechanism.
In the context of the follow-up action to the external evaluation, I was requested by the
Management Board to conduct an analysis of the situation of the Reitox network — on
the needs of the network, the improvements required and the future actions to be carried
out. This initial analysis concluded that an in-depth external evaluation was required
which has now been agreed on in principle. A steering committee has been set up to
prepare the terms of reference for such an evaluation and to accompany the process.
In spite of the additional tasks resulting from the evaluation of the agency, the pace
of work and output in the drugs domain did not slacken.
In the epidemiological field, real progress was made on preparing the ground for
implementation in the Member States of five comparable key epidemiological indi-
cators by testing the draft guidelines and tools. A meeting organised in Lisbon with
the principal players in international drugs work advanced the task of identifying a
core set of harmonised indicators in the epidemiology field at international level
with the emergence of the so-called ‘Lisbon consensus document’.
Great strides were made in 2000 in the area of qualitative research — for which,
in many countries, there is no tradition in the drugs field. In July, the Centre pub-
lished a work in the Scientific Monograph series on the subject, entitled ‘Under-
standing and responding to drug use: the role of qualitative research’.
In the new synthetic drugs field, the agility and effectiveness of the early-warning
system and the tight cooperation between EMCDDA and Europol was demon-
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strated in July when preventive warnings were issued through national networks in
the Member States in response to the emergence of ‘ecstasy’ tablets containing very
high doses of MDMA. The agency’s risk-assessment work remained high on the
political agenda with two further substances, ketamine and GHB, formally referred
to the agency and Europol for risk assessment by the Portuguese Presidency of the
Council in April (under the terms of the 1997 joint action on new synthetic drugs).
In the demand-reduction field, focus on evaluation continued with new studies in
the field of treatment, outreach work and on-site testing of synthetic drugs. Train-
ing sessions on how to evaluate drug-prevention programmes were organised in
cooperation with Member States. The agency firmly believes that only when such
programmes are routinely evaluated can we be sure that money used to tackle the
drug problem is well spent.
Beyond the four walls of the EMCDDA, cooperation continued with the agency’s
six priority international partners in 2000. It was a great pleasure for me to sign a
memorandum of understanding (MOU) in March with the World Health Organisa-
tion through an exchange of letters with Mr Marc Danzon, the Director of the
WHO regional office for Europe. Discussions are now underway with the WHO on
joint projects such as programmes relating to drug abuse in prisons. In July, I was
pleased to sign an MOU with the Inter-American Drug Abuse Control Commission
of the Organisation of American States (CICAD-OAS). I have also taken up contact
with the rest of our priority partners — Europol, Interpol and the World Customs
Organisation — with a view to agreeing the contents of other MOUs.
Significant advances have also been made with regard to cooperation with the
central and east European countries (CEECs). As part of the post-evaluation action,
an enlargement strategy was drawn up and adopted by the Management Board in
September. The preparation phase includes a Phare–EMCDDA technical assistance
project, developed with the aim of preparing the candidate countries of central and
eastern Europe to take part in the activities of the agency. The project was
approved in December by the Commission and is due to commence in February
2001.
At the end of September, the Council of the EU approved the participation of Nor-
way in EMCDDA activities. I am delighted to welcome Norway on board and look
forward to working together from 2001.
The agency stands at the threshold of a new era — a new chairman, a new Bureau,
a new triennial work programme to be set in motion and a new organisational
structure to be put in place. At this point I would like to thank Franz J. Bindert, the
outgoing chairman of our Management Board, for his dedication to the agency
over the last three years and the inspiration and support he has provided to us all.
Although the year 2000 was demanding for the agency and its staff, considerable
progress has been made and we can now look forward to an exciting future and an
improved infrastructure within which to carry out our activities. I take this oppor-
tunity to thank all those who contributed to the results achieved.
Georges Estievenart
Executive Director, EMCDDA
January 2001
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Priority areas as listed in the
annex to the EMCDDA founding
Regulation (EEC) No 302/93
Priority area 1: Demand and
reduction of the demand for drugs
Consolidating and enhancing
achievements
Priority area 2: National and
Community strategies and policies
(with special emphasis on
international, bilateral and
Community policies, action plans,
legislation, activities and
agreements)
Developing achievements
Tasks as listed in Article 2 of the
EMCDDA founding regulation
A. Collection and analysis of
existing data
B. Improvement of data-comparison
methods
C. Dissemination of data
D. Cooperation with European and
international bodies and
organisations and with non-
Community countries
A. Collection and analysis of
existing data
Priority objectives as listed in the EMCDDA
1998–2000 work programme
Priority objective 1
Consolidating and improving the Centre’s
epidemiological and demand-reduction
information systems on the basis of agreed sets of
core data
(a) Current trends and patterns: monitoring traditional
illicit drugs
(b) New trends: setting up and developing a mechanism
for the information exchange, risk assessment and
control of new synthetic drugs
Priority objective 2
Consolidating and enhancing the Reitox network
in accordance with the decisions taken by the
EMCDDA Management Board
Priority objective 3
Improving and developing reliable and comparable
methods, data systems and key indicators
Priority objective 4
Improving the quality of the Annual report on the
state of the drugs problem in the European Union,
the visibility of the work of the EMCDDA and the
Reitox network and the dissemination of the
information collected and produced by the
EMCDDA
Priority objective 5
Developing structured cooperation with the
EMCDDA’s international partners and ensuring
synergies and complementarity with EU
programmes and activities, avoiding any
duplication of work
Priority objective 6
Developing tools and methodologies for
comparing interventions, legislation, strategies and
policies in the EU (including cost-effectiveness
evaluation)
EMCDDA 1998–2000 work 
programme
In 2000, the EMCDDA’s work in epidemiology focused on preparing the
ground for implementing in the Member States five comparable key
epidemiological indicators of the prevalence and adverse health
consequences of drug use, and on continuing to collect, analyse and
synthesise data on drugs and drug use, their consequences and
correlates. This related principally to priority objectives 1, 2, and 3 of the
1998–2000 work programme.
Major tasks included: producing and testing recommended draft tools and
guidelines to improve comparability of core data on the five key
indicators; synthesising epidemiological information for the Centre’s
Annual report; and managing projects or networks linked to the key
indicators or to complementary topics (such as emerging trends,
modelling incidence and spread of drug use, sociological and economic
analysis of drug markets, mapping of social exclusion, minorities and
drugs). Output included: publication of a scientific monograph on
qualitative research; complementary statistical tables of core
epidemiological data published on the web; and an updated web site on
qualitative research (QED).
Chapter 1
Epidemiology
Overview of how the activities described in this chapter relate 
to the priority objectives of the 1998–2000 work programme
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Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(a) Current trends and patterns: monitoring traditional illicit drugs
Epidemiological information systems
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the deci-
sions taken by the EMCDDA Management Board
Reitox support projects
Priority objective 3
Improving and developing reliable and comparable methods, data systems
and key indicators
Epidemiological key indicators
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activ-
ities, avoiding any duplication of work
Cooperation in the field of epidemiology
Epidemiological information systems
In 2000, the EMCDDA’s work in this area included: collecting and synthesising
epidemiological data for the Centre’s 2000 Annual report; developing complemen-
tary statistical tables of core epidemiological data for web publication; consolidat-
ing networks of researchers to improve collection, analysis and exchange of quali-
tative and quantitative information; and carrying out projects to increase policy
relevance through data analysis.
Collecting and analysing data for decision-makers
Data collection and analysis for the EMCDDA’s 2000 Annual report
The main task involved synthesising epidemiological information from the Reitox
national focal points (NFPs) and other sources on: the extent, characteristics and
trends of drug use; on major health and social consequences and correlates; and
on illicit drug markets and drug availability. A section on the special topic of
women drug users and their children was prepared, and complementary statistical
tables of core epidemiological data for the 15 Member States were published on
the EMCDDA’s web site to coincide with the launch of the 2000 Annual report.
Emerging trends in drug use and qualitative research on drug-use
patterns
Work on emerging trends aimed at a more focused and practical approach to col-
lecting and analysing information. A feasibility study was carried out of the youth
media as an information source testing a prototype ‘Emerging trends bulletin’ for
collecting, disseminating and confirming recent information, in this case on
cocaine and crack (special topic for the 2001 Annual report). Involving France,
Italy and the UK, the study included strengthening links with existing networks —
telephone helplines (European Foundation of Drug Helplines), toxicologists, out-
reach workers — analysing data from school surveys, and a small expert meeting
to review selected trends and the potential value of the bulletin.
The EMCDDA’s work on qualitative research was consolidated in 2000 through up-
dating the QED web site http://www.qed.org.uk (bibliography, research inventories
and overviews) and the continued animation of a network of qualitative researchers.
The EMCDDA’s Scientific Monograph series, No 4: ‘Understanding and responding
to drug use: the role of qualitative research’ was published in July. An Insights publi-
cation on risk behaviours and health was prepared and will be published in 2001.
Under the joint action on new synthetic drugs, epidemiological and social data
were collected and analysed for the risk assessment of GHB and ketamine.
Dynamic modelling of drug use, its spread, consequences and costs
A study was completed on the incidence of problem drug use and latency time to treat-
ment. Funding from the European Commission’s targeted socioeconomic research
(TSER) programme enabled the Centre to consolidate work with research networks of
modellers on prevalence and incidence methodology, on geographical and temporal
diffusion of drug use, and on economic modelling, social costs and cost-effectiveness
and drug markets (see also below). Four meetings were held during the year. Progress
reports are available and a synthesis of the results will be completed in 2001. 
EMCDDA’s Scientific Monograph series, No 6: ‘Modelling drug use: methods to quan-
tify and understand hidden processes’ was completed and will be published in early
2001.
Drugs and social exclusion, focusing on minorities
A project — focusing on minorities — was completed to map available information on
social exclusion and drugs. Two expert meetings were held, one funded by the Euro-
pean Commission’s Research DG. The results are scheduled for publication in 2001.
Drug markets and drug availability
Two pilot projects were completed during 2000, one describing the characteristics
of local drug markets, the other a macroeconomic analysis of European heroin
markets and the possible impact of substitution treatment. Two small expert meet-
ings were held, one to discuss potential indicators of drug markets and availability
that might be developed by the Centre, the other (with TSER funding) to examine
the development of economic and other models of drug markets.
Law-enforcement statistics as epidemiological indicators
A revised information map was developed for the NFPs to identify information
sources and data flow for law-enforcement and criminal-justice system indicators.
The analysis will be available in 2001 and should help the EMCDDA improve col-
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lection and analysis of existing data. Information on drug users in prison was col-
lected and analysed.
Drug flows and total drug consumption
The Centre contributed to a study by the Financial Action Task Force on Money
Laundering (FATF) on estimating money laundering related to drugs by providing
available EU information on prevalence and consumption. It also cooperated with
the UK national focal point on a feasibility study of flows of heroin and cocaine in
the EU by providing methodologies and provisional estimates of total consump-
tion.
Data protection issues and epidemiological data
A small study was launched to examine issues concerning data protection and epi-
demiological data collection. The results are expected in mid-2001.
Reitox support projects
Work with the Reitox network included strengthening the NFPs’ involvement in
preparation for implementing the five key indicators, improving evaluation criteria
and feedback to NFPs on national reports (1), identifying information sources for
law-enforcement and criminal-justice system indicators, and developing data col-
lection on emerging trends.
Implementation of five key epidemiological indicators
Recommended draft tools and guidelines
At the end of 2000, the EMCDDA presented its recommended draft tools and guidelines
for the five key indicators to be implemented by Member States. These were examined
by the Scientific Committee and were to be considered by the Management Board in
January 2001. A report was also submitted to the Horizontal Working Party on Drugs
(HWPD) in the Council, as required by the EU action plan on drugs (2000–04).
Coordination, monitoring and EU-level expert groups
The EMCDDA continued to coordinate and monitor efforts to establish comparable
collection and reporting of core epidemiological data by Member States. This
included establishing: EU-level expert groups per indicator, in which all NFPs or
their nominated experts participate; progress reports from NFPs and bilateral dis-
cussions on specific issues; and regular updates on the situation for the Manage-
ment Board. The German and Dutch national focal points assisted in the coordi-
nation and technical work on three indicators (prevalence estimates, demand for
treatment and drug-related deaths).
Reporting by NFPs
Guidelines for the 2000 Reitox national reports and for statistical tables were mod-
ified and provided to the NFPs for their contribution to the Centre’s 2001 Annual
General report of activities 2000
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(1) National reports produced by the national focal points (as one of the Reitox core tasks) describe the drug situa-
tion in an EU Member State and provide core data for the EMCDDA’s Annual report and other analyses.
report. Evaluation criteria for national reports were developed and discussed with
the NFPs and the Scientific Committee, and feedback to NFPs improved. The
revised information map on sources for law-enforcement and criminal-justice sys-
tem indicators was also provided to NFPs.
Efforts to develop and improve the collection and reporting of data on emerging
trends by NFPs continued, with particular attention to cocaine and crack (see
above, especially the pilot ‘Emerging trends bulletin’).
Epidemiological key indicators
In 2000, the EMCDDA concentrated on field testing and finalising draft guidelines
and technical tools for the five key epidemiological indicators, monitoring prepa-
rations for their implementation by Member States, and starting to examine suitable
instruments for collecting, storing, analysing and disseminating the data.
Drug use in the general population
A European manual on general population surveys on drug use, including core
questionnaire items and methodological guidelines, was completed and will be
published in 2001. Work continued to develop an EU databank as an instrument
for collecting, storing and analysing core data in comparable format from national
population surveys, and to lay the basis for in-depth comparative analyses of the
data (contractor: Quinx Research, the Netherlands).
Prevalence estimates of problem drug use
Draft guidelines on national and local prevalence estimates had already been com-
pleted in 1999. Work continued with the EU expert group and the German
national focal point to test methods and update national estimates of problem drug
use in Member States. A feasibility study was completed of longitudinal studies on
changing patterns of use, health risks, careers and needs in young problem drug
users, which resulted in a common core questionnaire based on existing European
studies. The TSER research network on national and local prevalence estimation
continued the development of new methods (see above).
Demand for treatment by drug users
With the assistance of the German national focal point and the EU expert group,
the EMCDDA–Pompidou Group standard protocol 2.1 on the treatment demand
indicator was completed and field-tested by collecting and analysing data from 12
Member States. More in-depth analysis of selected aspects was explored and fur-
ther steps towards implementation made.
Drug-related deaths and mortality among drug users
Acute, drug-induced deaths
Draft guidelines for reporting acute drug-induced deaths from general mortality
and special (e.g. forensic) registers using the ninth edition of the international clas-
sification of diseases (ICD-9) were completed and field-tested with the help of the
EU expert group and the Dutch national focal point. More detailed analysis was
conducted on the impact of criteria used in the different Member States. Guide-
lines for ICD-10 were discussed and cooperation with Eurostat continued.
Chapter 1: Epidemiology
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Mortality and causes of death among cohorts of drug users
Coordination of cohort studies in different countries continued, including imple-
mentation of new studies, follow-up and analysis of existing cohorts, and propos-
als for extending methods and outputs to cover broader populations and to include
hospital admissions as well as deaths (contractor: Osservatorio Epidemiologico
Regione Lazio, Italy).
Infectious diseases among injecting drug users (IDUs)
Improved guidelines for reporting HIV and hepatitis B and C prevalence rates
among injecting drug users from a defined list of sources were produced and tested
with the assistance of the EU expert group (contractor: Scottish Centre for Infection
and Environmental Health, UK). A draft proposal was developed for the surveil-
lance of hepatitis C through community-wide surveys. Cooperation continued with
EuroHIV (formerly European Centre for the Epidemiological Monitoring of AIDS).
Cooperation in the field of epidemiology
Working with European and international partners
In the field of epidemiology, cooperation was fostered throughout 2000 with a
range of partners, including: services of the European Commission (Eurostat, Direc-
torate-General for Research); Europol; the United Nations International Drug Con-
trol Programme (UNDCP); the Pompidou Group of the Council of Europe; Euro-
HIV; Unaids; World Health Organisation (WHO), Inter-American Drug Abuse
Control Commission (CICAD), Financial Action Task Force on Money Laundering
(FATF), Global Research Network on HIV Prevention in Drug Using Populations,
and the US National Institute on Drug Abuse (NIDA).
General report of activities 2000
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Studies and reports, 2000
Epidemiology
General population surveys indicator
• Creation of a European Union databank on population surveys on drug
use, and joint analysis of data collected (Quinx Research), November
2000
• Scientific editing of a European manual with EMCDDA standard instru-
ments and guidelines to estimate drug use among the general population
(Quinx Research), November 2000
• Technical implementation and updating of the European Union databank
on national population surveys on drug use, and a joint analysis of data
collected (Quinx Research), to be published in 2001
Prevalence estimates indicator
• Project to start implementation of methods for estimating national preva-
lence of problem drug use in EU Member States (Institut für Thera-
pieforschung), March 2000
• Continuation of implementation of methods for estimating national preva-
lence of problem drug use in EU Member States (Institut für Thera-
pieforschung), to be published in 2001
Treatment demand indicator
• Coordination of the implementation of the EMCDDA–Pompidou Group
standard protocol on the treatment demand indicator (TDI) in the EU
Member States, and collection and analysis of treatment demand informa-
tion (Institut für Therapieforschung), November 2000
• Coordination of a new phase of implementation of the key epidemiologi-
cal indicator ‘drug treatment demand’ in the EU Member States (Institut für
Therapieforschung), to be published in 2001
Drug-related deaths indicator
• Coordination of the implementation of the EMCDDA guidelines on the
drug-related deaths indicator in the EU Member States, and the collection
and analysis of information on drug-related deaths (Trimbos-instituut),
November 2000
• Continuation of development of EMCDDA standard guidelines on the
drug-related deaths and coordination of their implementation by Member
States (Trimbos-instituut), to be published in 2001
Mortality indicator (cohort studies)
• Mortality of drug users in the European Union: coordination of implemen-
tation of new cohort studies, follow-up and analysis of existing cohorts
and development of new methods and outputs (Agenzia di Sanità Pubblica
— Regione Lazio), November 2000
• Mortality of drug users in the European Union: coordination of implemen-
tation of new cohort studies, follow-up and analysis of existing cohorts
and development of new methods and outputs (Agenzia di Sanità Pubblica
— Regione Lazio), to be published in 2001
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Infectious diseases indicator
• Project to improve collection of data on the key indicator hepatitis B and
C and HIV in injecting drug users (Scottish Centre for Infection and Envi-
ronmental Health), November 2000
• Continuation of the project to improve collection of data on the key indi-
cator hepatitis B and C and HIV in injecting drug users (Scottish Centre for
Infection and Environmental Health), to be published in 2001
Statistical and dynamic modelling
• Study on incidence of problem drug use and latency time to treatment in
the European Union (University of Rome ‘Tor Vergata’), November 2000
• Macroeconomic analysis of heroin markets in the EU and the impact of
substitution treatment (Modus Vivendi), December 2000
• TSER drug use modelling network: third progress report, June 2000; fourth
progress report, December 2000 (EMCDDA, Institut für Thera-
pieforschung, University of Glasgow, University of Keele, University of
Rome ‘Tor Vergata’, RIVM, University of York)
Qualitative research
• Maintenance, update and development of the European web site and net-
work for qualitative research — http://www.qed.org.uk (Dr Jane Fountain),
November 2000
• Prolongation of previous contract for the maintenance, update and devel-
opment and migration of the European web site and network for qualita-
tive research to the EMCDDA — http://www.qed.org.uk (Dr Jane Foun-
tain), to be completed by June 2001
• Feasibility study on monitoring youth media as a source of information for
detecting, tracking and understanding emerging trends (Gruppo Abele),
November 2000
Emerging trends
• Feasibility study on the implementation of longitudinal studies on chang-
ing patterns of use, health risks, careers and needs in young problem drug
users (Trimbos-instituut), November 2000
Other projects
• Project to map available information on social exclusion and drugs, focus-
ing on minorities in the 15 Member States of the European Union
(DrugScope), December 2000
• Pilot project to describe and analyse local drug markets (Max-Planck-Insti-
tut), November 2000
• Study of the implications of data protection legislation for epidemiological
information systems on drugs (DrugScope), to be published in October
2001
Chapter 1: Epidemiology
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Major meetings organised by the EMCDDA, 2000
Epidemiology
Date Place Event
20–21 January EMCDDA Drug demand epidemiology: global consul-
tation meeting on consensus and partner-
ship building with UNDCP
3–5 February Munich Expert meeting on key indicator: national
prevalence estimates of problem drug use
(TSER–EMCDDA–Institut für Therapiefors-
chung)
Expert meeting: dynamic modelling of time
trends and incidence
(TSER–EMCDDA–University Rome Tor Ver-
gata)
25–26 February Brussels First project meeting: mapping available
information on drugs and social exclusion,
focusing on minorities
6–7 April Turin First project meeting: feasibility study on
monitoring youth media as new sources of
information for detecting, tracking and
understanding emerging drug trends 
11 April Jersey First project meeting: cohort studies of
young problem drug users (EMCDDA–Trim-
bos-instituut)
13 April Jersey Expert meeting: geographic spread and
geographic information systems, diffusion
of problem drug misuse (TSER–EMCDDA–
Keele University)
27–28 April Barcelona Expert meeting: prevalence of problem
drug use at local level (TSER–EMCDDA–
CDMR)
7–11 May Rome Project meeting: time trends and incidence.
Meeting to work on scientific publications 
on incidence and latency time estimation 
(EMCDDA–University of Rome Tor Vergata)
11–12 May Amsterdam Expert meeting to develop proposals for
joint analysis based on the European data-
bank on population surveys 
15–16 June EMCDDA Second expert meeting: cohort studies of
young problem drug users (EMCDDA–Trim-
bos-instituut)
22–23 June EMCDDA EU expert group annual meeting on key
indicator: drug-related infectious diseases
(hepatitis B/C and HIV) 
22–23 June Rome Discussion of proposal to be submitted to
the European Commission (Research DG)
for the continuation and improvement of
cohort mortality studies on drug addicts in
treatment
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23 June Brussels Project meeting: macroeconomic analysis
of heroin markets in the EU and the impact
of substitution treatment 
29–30 June EMCDDA EU expert group annual meeting on key
indicator: demand for treatment by drug
users
8–9 September Turin Second project meeting: feasibility study on
monitoring youth media as new sources of
information for detecting, tracking and
understanding emerging drug trends 
15 September Brussels Project meeting: macroeconomic analysis
of heroin markets in the EU and the impact
of substitution treatment 
28–29 September EMCDDA Second project meeting: mapping available
information on drugs and social exclusion,
focusing on minorities
29–30 September Munich European steering group meeting on further
implementation process of the treatment
demand indicator
16–17 October EMCDDA EU expert group second meeting on key
indicator: drug-related infectious diseases
(hepatitis B/C and HIV)
23–24 October EMCDDA Expert meeting: drug markets and model-
ling (EMCDDA–TSER–York University)
13 November Amsterdam Meeting with RIVM: drug-related infectious
diseases 
23–24 November EMCDDA EU expert group annual meeting on key
indicator: drug-related deaths
28 November EMCDDA Expert meeting: drug markets and drug
availability 
4–5 December EMCDDA Expert meeting: emerging trends and quali-
tative research
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Major meetings attended by the EMCDDA, 2000
Epidemiology
Date Place Event
23–24 February Granada International conference on heroin and
new trends in opioid agonists, Escuela
andaluza de salud pública
23–24 February Paris FATF technical workshop on estimating
drug trafficking proceeds
7 April London Conference on ‘Reducing harm from alco-
hol and drugs: making the research policy
and practice connections’, organised by the
Centre for Research on Drugs and Health
Behaviour
9–12 April Jersey 11th international conference on the reduc-
tion of drug-related harm
14–15 April Rotterdam Conference on ‘Sexually transmitted dis-
eases in a changing Europe’
27–29 April Barcelona Conferencia de consenso sobre reduccion
de daños relacionados con las drogas:
cooperación e interdisciplinariedad
10–12 May Lisbon First quality conference for public adminis-
trations in the EU, sharing best practices,
organised by the Portuguese Presidency of
the EU
18 May The Hague Meeting of the reflection group on align-
ment of law-enforcement drug statistics,
Europol
22–23 May Strasbourg 30th meeting of experts in epidemiology of
drug problems, Pompidou Group
22–24 May Vienna Expert meeting on ‘Dynamic drug policy:
understanding and controlling drug epi-
demics’, Technical University
Vienna–UNDCP
24 May Strasbourg Meeting of the Mediterranean network,
Pompidou Group
31 May–3 June Banff, Third international symposium on the eco-
Canada nomic and social costs of substance abuse
organised by the Canadian Centre on Sub-
stance Abuse 
5–7 July Durban,  Third annual meeting of the global research 
South Africa network on HIV prevention in drug-using
populations organised by NIDA, WHO 
9–14 July Durban, 13th international AIDS conference
South Africa
24–25 July London Drafting meeting on the revision of the
Annual report questionnaire, Part II,
UNDCP and CICAD
21–23 Dublin 11th annual conference of the European 
September Society for Social Drug Research
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10–11 Brussels Horizontal Working Party on Drugs and 
October launch of EMCDDA Annual report
13 October London Meeting on dance drugs, London Toxicol-
ogy Group
18 October Münster Seminar ‘Rauschgiftkriminalität’, organised
by Polizei-Führungsakademie
10–11 November Amsterdam Fourth international hepatitis C conference
organised by Mainliners, supported by
EMCDDA
Articles published, 2000
Epidemiology
Hartnoll, R., Letter to the editor entitled ‘The Swiss heroin trial: scientifically
sound?’, Journal of Substance Abuse Treatment, Vol. 19, No 3, 2000, pp.
210–211.
Griffiths, P., Vingoe, L., Hunt, N., Mounteney, J. and Hartnoll, R., ‘Drug infor-
mation systems, early warning, and new drug trends: can drug monitoring sys-
tems become more sensitive to emerging trends in drug consumption?’, Sub-
stance Use & Misuse, Vol. 35, Nos 6–8, 2000, pp. 811–844.
Wiessing, L., ‘Prevention of HIV, HBV, and HCV in injection drug users in the
European Union’, Global Research Network Meeting on HIV Prevention in
Drug-Using Populations, August 26–28 1999, Atlanta, United States, Second
Annual Meeting Report, 2000, pp. 35–38.
In 2000, the EMCDDA’s work in the field of drug demand reduction
corresponded primarily to priority objectives 1, 2, 3 and 5 of the 1998–2000
work programme. The consequences for the work of the EMCDDA of the
introduction of the EU action plan on drugs (2000–04) were also analysed.
The EMCDDA databases on demand-reduction activities were further
developed, both contentwise and technically. The focus on evaluation
continued with new studies in the field of treatment, outreach work and
on-site testing of synthetic drugs. Training sessions on evaluation were
organised in cooperation with the Member States. A study on assistance
to drug users in prisons was completed and a preliminary study on ‘Roles,
structures and cooperation in the field of demand reduction’ was finished,
laying the ground for a study covering all EU countries.
Finally, through participation in European, national and regional meetings,
the Centre succeeded in heightening the impact of its demand-reduction
activities, which are increasingly recognised by both policy-makers and
professionals in the field.
Chapter 2
Demand reduction
Exchange on drug demand-reduction action (EDDRA)
In order to facilitate consultation of the EDDRA database by a wide Internet au-
dience, multilingual access to the database was developed, search functions in
line with the EMCDDA web site standards introduced, and the EDDRA off-line ed-
iting tool improved. The Luxembourgish national focal point was commissioned
with this task. A new layout for EDDRA was introduced in February 2000 and the
latest version of the EDDRA off-line tool for national managers (Version 1.0.5) was
released in May. The database has been running in all EU languages since the end
of July.
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Overview of how the activities described in this chapter relate to the
priority objectives of the 1998–2000 work programme
Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(a) Current trends and patterns: monitoring traditional illicit drugs
Exchange on drug demand-reduction action (EDDRA)
Roles, structures and cooperation of drug demand-reduction services
Assistance to drug users in prisons
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
On-the-spot pill-testing interventions
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the deci-
sions taken by the EMCDDA Management Board
Evaluation and EDDRA training
Priority objective 3
Improving and developing reliable and comparable methods, data systems
and key indicators
Evaluating outreach work
Evaluation Instruments Bank (EIB)
Women in drug treatment
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activ-
ities, avoiding any duplication of work 
Cooperation with the European Commission
EDDRA is a Reitox core task and the EDDRA management group agreed a working
plan during its coordination meeting in March which included the objective to
double the number of projects in the database in 2000 and to improve the quality
of the data produced. The second meeting of the EDDRA managers, in December,
dealt with minimum evaluation criteria, abstraction techniques and the promotion
of EDDRA in the Member States.
At the end of 1999, the database included 144 programmes, of which 105 had
been revised by the national managers. In 2000, the Member States and the Euro-
pean Commission provided 219 new programmes. The new programmes cover,
among others, new synthetic drugs prevention, social and professional support of
drug addicts and harm-reduction initiatives.
Roles, structures and cooperation of drug 
demand-reduction services
The preliminary study on ‘Roles, structures and cooperation of drug demand-
reduction services’ commenced in January 2000. France, Portugal and the
United Kingdom were selected as case studies (contractor: Rand Europe, the
Netherlands). The main goal of the study was to construct, validate and refine an
instrument for future data collection. The selected instrument — an interview
protocol — was tested in around 25 interviews in the three countries. The study
concluded that the interview protocol was a useful instrument for a comparative
study across the EU but also emphasised that the implementation study, to 
be launched by the end of the year and intended to collect data from all EU
Member States, could only be carried out with adequate resources. Given 
the complexity of this area, interviewers familiar with the drug policy of the 
respective country and face-to-face interviews were seen as a prerequisite for
successful results.
Assistance to drug users in prisons
The EMCDDA has developed mapping studies to assess the information available
on the status of drug users in the criminal justice system in the EU. A new study on
‘Assistance to drug users in EU prisons’ (contractor: University of Oldenburg, Ger-
many) aims to collect information on the prisoners’ state of health, drug use and
drug-related harm, prevention and treatment, as well as best practice and standards
of evaluation.
A first step to implementation was a seminar organised by the EMCDDA in Decem-
ber 1999. Participants were invited to provide their input on key concepts,
methodological aspects, information sources as well as promotion of results.
A research strategy was adopted for the study based on the collection of exist-
ing written material as well as primary data. EMCDDA databases (EDDRA and
QED), prison services, umbrella organisations in Europe, universities, archives,
international organisations and networks were all consulted. Targeted questions
were transmitted to scientific and professional experts in the field and to min-
istries of justice and health. The final report will be available at the beginning
of 2001.
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On-the-spot pill-testing interventions
The aim of this project is to draw up a comprehensive inventory of on-site pill-test-
ing interventions in the EU (contractors: Verein Wiener Sozialprojekte and
CheckIt!, Austria). Eighteen organisations already involved in pill-testing projects or
with firm plans to set one up were identified and sent questionnaires. Organisa-
tions involved include DIMS (the Netherlands), Médécins du Monde (France),
Modus Vivendi (Belgium), and Eve and Rave (Germany). The objectives, evaluation
indicators, target groups, methodology, potential and pitfalls of ongoing pro-
grammes were examined with a view to assessing how pill-testing projects can be
used for harm-reduction and prevention purposes and how the information pro-
vided through the EMCDDA joint action on new synthetic drugs can be channelled
into daily demand-reduction practice. The study’s report aims to provide informa-
tion on: which pill-testing procedures can or should be used for which aims; which
pill data should be made available to the public; how best to evaluate the proce-
dures being used for pill-testing and prevention messages at large; and opportuni-
ties to collaborate and exchange knowledge among and between the projects and
the EMCDDA. The final report will be made available on the EMCDDA web site in
2001.
Evaluation and EDDRA training
Evaluation and EDDRA training sessions were organised in three Member States in
2000. They aimed to develop a deeper commitment towards evaluation from EU
professionals and policy-makers. The seminars targeted professionals with a peer-
leader function in regions or leading institutions of the Member States. Another
objective is to make regional decision-makers aware of evaluation practice as well
as to collect feedback and suggestions from the field. This enhanced the coherence
between the EMCDDA and national and regional policy implementation. The
training sessions were organised by the national focal points and co-financed by
the EMCDDA. Training sessions were carried out in Ireland (20 participants), in
Italy (50 participants) and in Denmark (25 participants). Each focal point’s national
priorities were reflected in the aims and organisation of the training seminars.
Focal point representatives were satisfied with the training sessions and welcomed
the increased visibility that such types of events bring to their work at national
level. EMCDDA staff intensified links to key persons in regional policy and
demand-reduction practice.
Evaluating outreach work
Evaluating outreach projects is still in its infancy in most EU Member States but
evidence presented in the EMCDDA’s Insights publication, ‘Outreach work among
drug users in Europe’ (ISBN 92-9168-062-1) reveals that the most urgent need of
the projects is how to improve the practice of outreach work.
In a follow-up study to this study on outreach work, the Centre for HIV/AIDS and
Drugs Studies (UK) and the University of Amsterdam were commissioned to
develop evaluation guidelines for outreach work, in line with the EMCDDA strat-
egy to provide assistance and tools to professionals. Evaluating outreach work has
special requirements which makes it necessary to adapt existing EMCDDA tools
and to complement them with new instruments. The project aims to facilitate data-
collection methods, develop evaluation guidelines and tools, and create training
and cooperation opportunities. The development of the guidelines takes into
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account the particular needs of an intervention setting where evaluation is difficult.
The guidelines focus on the process through which individual projects assess and
reflect on their performance and are aimed at outreach project managers and staff,
principally for self-evaluation in consultation with stakeholders.
Evaluation Instruments Bank (EIB)
In 2000, the EIB was integrated into the EMCDDA public web site. It is a 
document-base of tools designed to encourage evaluation using reliable methods
and to help to standardise them. The EIB contains tools for evaluating both pre-
vention and treatment programmes. The user enters the specific criteria of the in-
tervention to be evaluated and the search result provides the most suitable eval-
uation tool, together with comments on its use and references to related studies.
The EIB was updated in July 2000 and to date contains 31 instruments in the field
of prevention and 184 instruments in the field of treatment. Although most of the
instruments (two thirds) are currently in English, the document bank has been 
designed to be flexible and expandable, thereby allowing for the continuous 
addition of different language versions and also the introduction of instruments
for specific settings.
Women in drug treatment
At the 45th permanent correspondents meeting, in March 2000, the secretariat of
the Pompidou Group of the Council of Europe was given the mandate to discuss,
with the EMCDDA, ways to implement follow-up actions regarding the topic of
women and drugs. By February 2000, the Pompidou Group had finalised a report
on ‘Community-based services for female drug users in Europe’, a compilation of
case studies and guidelines for good practice. In June 2000, the EMCDDA pro-
posed to draft an introduction to this report and to develop internally a ‘needs
assessment guide for female users of drug services’. The guide aims to support pol-
icy-makers in planning drug services taking into account the specific needs of
women. Both outputs will be included in the respective web pages of the two
organisations.
Cooperation with the European Commission
Strengthening cooperation with the Health and Consumer Protection Unit in
charge of the Community action programme for the prevention of drug depend-
ence was a priority task for 2000. In order to ensure a smooth flow of information,
bilateral quarterly meetings were organised where activities have followed along
two main lines. On the one hand, the EMCDDA provided scientific material to the
Commission on the drug phenomenon and responses for its preparation of draft
recommendations on drug public-health responses. On the other hand, the Com-
mission services participated actively in the EDDRA project and submitted six pro-
grammes that were inserted into the database.
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Studies and reports, 2000
Demand reduction
• ‘Improving evaluation skills using EMCDDA guidelines for evaluation of
demand-reduction activities and the EDDRA system in Italy, Denmark and
Ireland’
• ‘Evaluation: a key tool for improving drug prevention’
• ‘Reviewing current practices in drug-substitution treatment in the EU’
• Workbooks ‘Evaluation of psychoactive substance use disorder treatment’
(Cooperation between WHO, UNDCP and EMCDDA)
• ‘Inventory of on-site pill-testing interventions in the EU’
• ‘Measuring the roles, structures and cooperation of drug demand-reduc-
tion services: results of a preliminary study’
• ‘Assistance to drug users in prison’
• ‘Evaluation guidelines for outreach work’
Major meetings organised by the EMCDDA, 2000
Demand reduction
Date Place Event
30–31 March EMCDDA EDDRA managers meeting
6–8 April EMCDDA Board meeting of the European Foundation
of Drug Helplines (FESAT)
29–30 September EMCDDA Guidelines for the evaluation of outreach
work workshop
4–5 December EMCDDA Meeting of the qualitative research
network (QED)
7–8 December EMCDDA EDDRA managers meeting
Major meetings attended by the EMCDDA, 2000
Demand reduction
Date Place Event
20 January Madrid Seminar on ‘The gypsy community and
drug addiction’
27–29 January Braga International congress, ‘Os mundos sociais
e culturais da infância’
4 February Porto European conference, Federation of
European Professionals Associations
Working in the Field of Drug Abuse (ERIT)
5 February Rome International Reference Group (CeIS)
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25 February Brussels Collège médical interinstitutionnel
28–29 February Brussels Interinstitutional conference on drugs
policies in Europe
10 March Lisbon Training seminar in evaluation for
professionals of the Serviço de
Prevenção e Tratamento da
Toxicodependência (SPTT)
16 March Luxembourg Committee meeting of the programme of
community action on the prevention of
drug dependence in the framework of
public health 
13–17 March Lisbon EDDRA off-line training with the
Portuguese demand-reduction networks
20 March Bern WHO (Europe) health in prisons project
18–19 May Dublin Evaluation and EDDRA training seminar
30 May Brussels Horizontal Working Party on Drugs
31 May–3 June Montreal Society for Prevention Research, eighth
annual pre-conference workshops
meeting
1–7 June Luxembourg Multinational networks in the field of
drug prevention
5–6 June Verona Evaluation and EDDRA training seminar
8–9 June Odense Evaluation and EDDRA training seminar
19 June London Conference on women and drugs
22–24 June Alcorcón Fifth ‘Jornadas de prevención de
drogodependencias’
30 June Luxembourg Collège médical interinstitutionnel
3–4 July Brussels Exploratory meeting with international
organisations
6–8 July San Sebastian Summer school of the Basque University
on drug prevention policies
8–12 July Birmingham British prison drug workers’ conference
20–21 July Oviedo Workshop on social impact of legal
drugs
7–8 September Malmö Cooperation against drugs, organised by
European Cities Against Drugs (ECAD),
Nordic Branch
22–24 September Rome International Reference Group (CeIS)
10 October Brussels Multi-stakeholder conference, Future
health strategy
16–17 October Bologna European meeting, Evaluation of services
for drug addictions
6–7 November Madrid Seminar on evaluation and quality
indicators
13–15 November Karlsruhe DHS Fachkonferenz Sucht 2000
23–24 November Venice Training on prevention quality and
evaluation
23–25 November Athens WHO Adequacy in drug abuse
treatment and care in Europe (ADAT)
conference
27 November Stockholm Meeting of technical advisory network of
Mentor Foundation
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Articles published, 2000
Demand reduction
Burkhart, G., ‘First childhood interventions — possibilities and experiences in
Europe’, Toxicodependências, Vol. 6, No 2, 2000, pp. 33–46.
Burkhart, G., ‘Intervenções na primeira infância: experiencias realizadas na
Europa sobre prevenção de drogas’, Actas do Congresso Internacional ‘Os
mundos Sociais e Culturais da Infância, Vol. 3, Instituto de Estudos da Cri-
ança, Universidade do Minho, Braga (Portugal), 2000, pp. 53–58.
Burkhart, G., ‘Programación y evaluación, instumentos y claves para la
mejora de los programas preventivos’, De Arce, F. (Ed), Ponencias de las IV
Jornadas sobre prevención de drogodependencias, Ayuntamiento de Alcor-
cón, Comunidad de Madrid, 2000, pp. 85–90.
Burkhart, G., ‘Calidad en programas de prevención: evaluación, diseño, doc-
umentación y visibilidad’, De Arce, F. (Ed), Ponencias de las IV Jornadas sobre
prevención de drogodependencias, Ayuntamiento de Alcorcón, Comunidad
de Madrid, 2000, pp. 275–286.
Nilson, M., Zur Europäischen Beobachtungsstelle für Drogen und Drogen-
sucht — EBDD, BINAD–Information, Vol. 17, January–May 2000, pp. 41–47.
Nilson, M., Editorial, IDEA Prevención, No 19, July–December 1999, pp. 5–7.
Solberg, U., ‘Visitation i Danmark’, Stof, No 12, Copenhagen, September
2000, pp. 8–9.
Solberg, U., ’Substitutionsbehandling i EU’, Stof, No 13, December 2000,
pp. 24–25.
The main work of the Reitox coordination department in 2000
corresponded to priority objectives 2 and 4 of the 1998–2000 work
programme. Progress was achieved on a two-way discussion process and
exchange of information between the EMCDDA and the network, as well
as the further involvement of the Reitox focal points in general EMCDDA
work programming (e.g. the 2001–03 work programme). The EMCDDA
evaluation and internal reform process and further discussions on the role
of the Reitox network stimulated these developments. Work focused on
the qualitative aspects of data and reporting, and more structured systems
were set in place with common criteria and a feedback mechanism.
The analysis of the Reitox network, carried out by the director at the
request of the Management Board and in cooperation with the Member
States and the national focal points, provided for reflection on the needs
of the network, the improvements required and future actions to be
undertaken. On the basis of this analysis, the Management Board decided
to create a Reitox steering group (composed of representatives of the
Management Board, Scientific Committee, Reitox focal points and the
EMCDDA executive director) to draw up the terms of reference for an
external evaluation of the Reitox focal points. These were to be presented
to the Management Board for discussion and approval in early 2001.
Chapter 3
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Overview of how the activities described in this chapter relate to the
priority objectives of the 1998–2000 work programme
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the deci-
sions taken by the EMCDDA Management Board
Core tasks
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activ-
ities, avoiding any duplication of work
Preparation phase for the adhesion of the candidate countries
While the majority of the department’s activities focused on the above object-
ives, it also played a fundamental role in the execution of priority objectives
1, 3, 4 and 6
Other activities
Dissemination, networking and discussion
Core tasks
The Reitox coordination department’s primary role is to coordinate and animate
the Reitox network — composed of the 15 EU national focal points, the European
Commission focal point and the Norwegian focal point — and to assist them in
achieving their core tasks (defined in the Reitox ‘core tasks’ contract drawn up
between the EMCDDA and each Reitox national focal point annually).
In 2000, the five core tasks of the Reitox national focal points were:
• updating the national reports describing the national drug situation in 1999;
• actively participating in the progressive implementation of five harmonised 
epidemiological key indicators (see Chapter 1);
• actively participating in, and contributing to, the electronic information system
exchange on drug demand-reduction action (EDDRA) (see Chapter 2);
• participating at national level in the early-warning system on new synthetic
drugs foreseen by the 1997 joint action on new synthetic drugs (see Chapter 4);
• collecting information on data sources in the field of law enforcement and doc-
umentation centres (information maps).
National reports
The focal points drew up their national reports (covering the full year 1999) and
most of them updated information on the year 2000 regarding demand-reduction
activities, new trends, policy and legislation changes and key issues. The reports
were submitted to the EMCDDA by the end of October 2000 and provided the
Centre with vital data, among others, for its 2001 Annual report on the state of
the drugs problem in the European Union. The national reports included three
key issues which were selected at a special Reitox session in March 2000: drug
strategies in European Union Member States; cocaine and base/crack cocaine;
and infectious diseases. As part of the 2000 national reports, the NFPs also sub-
mitted their updated epidemiological standard tables to the EMCDDA in mid-
September.
During 2000, there were two important developments in this area — the introduc-
tion of a bilateral feedback process on the 1999 national reports and the develop-
ment of shared and coordinated guidelines for the 2001–02 reports.
Despite the differences between countries, the quality of information ranges from
sufficient to quite good and most of the information needed to obtain an overview
of the drugs situation in Europe is present. The main problems are related to
methodological issues such as data comparability and assuring the broad coverage
of new areas.
The guidelines for the preparation of the 2002 Annual report were presented to the
NFPs during the Reitox meeting in October and were finalised in December. The key
issues chosen are multiple drug use, successful treatments and drug users in prison.
These reflect the new targets defined in the EU action plan on drugs (2000–04) and
involve the focal points in information collection in new target areas.
Harmonised epidemiological key indicators
In 2000, the existing methods and instruments regarding the five harmonised epi-
demiological key indicators were reviewed and further developed. This included
the establishment of EU-level expert groups per indicator in which all national
focal points (or their nominated experts) participated (see Chapter 1).
The importance of this activity was highlighted in the EU action plan on drugs
(2000–04) which urged Member States, in cooperation with the EMCDDA, ‘to
enhance their efforts to provide reliable and comparable information on the key
epidemiological indicators in order to better evaluate the impact of drug-related
issues (2).’
Exchange on drug demand-reduction action (EDDRA)
In 2000, the EDDRA managers group concentrated on improving the quality of the
information made available, on increasing the number of projects or programmes
in the database, and on facilitating broad consultation of the information by the
general public. Attention was also paid to improving the existing contents. The
managers defined a shared quality framework for data compilation and worked in
subgroups on abstraction techniques; on minimum standards of evaluation; and on
advertising and promoting EDDRA. The material in the database doubled during
2000 and, for the first time, the Commission also introduced projects into it (see
Chapter 2).
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(2) Presidency Conclusions, Santa Maria da Feira European Council, 19 and 20 June 2000, SN 200/00, para. 51.
Joint action on new synthetic drugs
In 2000, the Reitox focal points regularly informed the EMCDDA on both the
progress and the functioning of the mechanisms implemented at national level.
Within the early-warning system on new synthetic drugs, Reitox focal points
were also requested to report against Article 3 of the joint action, i.e. to report
to the EMCDDA, in close liaison with Europol, the detection of new substances
in the EU.
The most important result in 2000 was the first global feedback on the joint ac-
tion on the basis of the progress reports provided by the NFPs during the year.
This feedback exercise is fundamental to improving the quality of data collected
and to the operation of the special network on new synthetic drugs. Focal points
were also informed by the EMCDDA on the outcome of the risk assessment con-
cerning the substances GHB and ketamine (see Chapter 4). The EU action plan
on drugs (2000–04) highlights the importance of the work already achieved
through the joint action and the need for improved cooperation between national
authorities.
Preparation phase for the adhesion of the candidate countries
The preparation of the adhesion of the candidate countries commenced in 2000
and has already achieved interesting results. The candidate countries provided
their national reports describing the drug situation at national level in 1999. The
methodology for adhesion was defined and presented to the Commission at the
end of November (see Chapter 8).
Dissemination, networking and discussion
Dissemination activity
The Reitox focal points are already actively involved in the dissemination of 
EMCDDA products on a voluntary basis. To date their main tasks in this area have
been:
• the distribution of publications to national and regional bodies, NGOs and pro-
fessionals;
• active participation in the launch of the Annual report (distribution of the
Annual report and news releases, responding to requests from journalists and
following up contacts, press clippings).
Further discussion took place in 2000 and it is foreseen that in 2001 the core tasks
will be extended to other objectives, especially increased participation of the NFPs
in the field of dissemination.
Common EMCDDA–Reitox electronic network
The common EMCDDA–Reitox electronic network, set up with funding from the 
European Commission’s interchange of data between administrations (IDA) 
programme, was increasingly used by the Reitox community (EMCDDA and national
focal points) for disseminating and exchanging information and promoting under-
standing and transparency within the network. The electronic services provided in
the private Reitox web site include: secure e-mail communication; transfer of meet-
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ing minutes, documents and data; agenda consulting; and participation in discussion
groups. During the year, the Reitox community prepared for the further extension of
services and applications as well as the smooth integration of new partners.
Meetings and cluster groups
Three meetings of the national focal points were held in Lisbon in 2000. They
focused on: the state of progress in achieving the core tasks; the contractual and
financial terms; the consequences of the internal EMCDDA reform process for the
Reitox network; and the future EMCDDA three-year work programme (2001–03).
Furthermore, a special working party took place in June, involving several national
focal points and EMCDDA staff, to brainstorm on how to improve the two-way
relationship between the Centre and the focal points. Finally, a cluster meeting
(topic-focused workshop) — involving the Belgian, French and Dutch national
focal points — was held in Brussels at the end of November. This cluster meeting
focused on data quality and networking, the objective of which was to define com-
mon standards and procedures in order to improve the quality of information and
to identify new and better means for networking. The intention is to extend the
abovementioned cluster meeting to the other focal points during 2001.
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Studies and reports, 2000
Reitox
• National focal point national reports for 1999
• National focal point reports on recent developments and trends, 2000
• National focal point reports on the implementation of the joint action on
new synthetic drugs at national level, 2000
• National focal point reports on the implementation of the information sys-
tem on demand-reduction activities, 2000
• National focal point work plans regarding the implementation of the epi-
demiological key indicators at national level, 2000
Major meetings organised by the EMCDDA, 2000
Reitox
Date Place Event
9–10 March Lisbon 19th meeting of the heads of the Reitox
national focal points
30–31 May Lisbon Extraordinary meeting of the heads of national
focal points
15 June Lisbon Reitox working party (improving the two-way
relationship with Reitox national focal points)
16–18 October Lisbon 20th meeting of the heads of the Reitox
national focal points
25 October Lisbon Reitox steering group (preparing the external
evaluation of the Reitox national focal points)
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Major meetings attended by the EMCDDA, 2000
Reitox
Date Place Event
20 June Luxembourg Meeting at the Luxembourgish national
focal point on ‘Improving the two-way
relationship with Reitox’
22 June Brussels Meeting at the European Commission focal
point on ‘Improving the two-way relation-
ship with Reitox’
23 June Brussels Meeting at the Belgian national focal point
on ‘Improving the two-way relationship
with Reitox’
5–6 July Rome Sports against drugs
17 July Brussels Reitox–IDA II project
18 July Brussels Meeting with Unisys on ‘Business solu-
tions’
27 November Utrecht Meeting with the Dutch national focal
point on ‘Qualitative data feedback and
global networking improvement’
28 November Paris Meeting with the French national focal
point on ‘Qualitative data feedback and
global networking improvement’
29 November Brussels Cluster meeting with Belgian and Dutch
national focal point on ‘Qualitative data
feedback and global networking improve-
ment’
12–13 December Rome Public policies against drugs in Europe
22 December Reggio Drug and at-risk behaviours 
Emilia
Articles written or papers delivered, 2000
Reitox
The following papers were presented at events during the year:
• Feedback on national reports 1999: ‘A first evaluation on data quality’
• Guidelines for the 2000 and 2001 national reports
• ‘Improving the two-way relationship with Reitox’, drafted at the Reitox
working party of 15 June 2000 and finalised following several meetings
with the national focal points
• Report from the Reitox steering group to the EMCDDA Management
Board, regarding the ‘External evaluation of the Reitox focal points’
• ‘Sport against drugs: the scientific basis for drug prevention in sport’,
Rome, 5–6 July 2000
• 2001–03 Reitox work programme (with active involvement of the national
focal points)
The principal activities carried out in this area relate to priority
objectives 1, 2, 5 and 6 of the 1998–2000 work programme.
In the area of drug-related legal information, collaboration with the
network of legal experts was formalised and the infrastructure for a legal
database on drugs developed. Two studies were finalised, one on the
prosecution of drug users and one on the costs of drug policy, scheduled
for publication in 2001. An extended section on drug law was added to
the EMCDDA web site.
In the area of new synthetic drugs two substances — ketamine and 
GHB — were formally referred to the EMCDDA and Europol for risk
assessment. The latter offered the Centre the opportunity to combine its
information-collection and scientific-evaluation expertise to influence
decision-making on drugs in the EU.
Work carried out in 2000 was undertaken by the section of the EMCDDA
attached to the director’s office responsible for new synthetic drugs,
international cooperation and legal information.
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Overview of how the activities described in this chapter relate to the
priority objectives of the 1998–2000 work programme
Priority objective 1
Consolidating and improving the Centre’s epidemiological and demand-
reduction information systems on the basis of agreed sets of core data
(b) New trends: setting up and developing a mechanism for the information
exchange, risk assessment and control of new synthetic drugs
Mechanism for the implementation of the joint action on new synthetic
drugs
Priority objective 2
Consolidating and enhancing the Reitox network in accordance with the deci-
sions taken by the EMCDDA Management Board
Joint action on new synthetic drugs and the Reitox network
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activ-
ities, avoiding any duplication of work
Cooperation in the field of new synthetic drugs and legal information
Priority objective 6
Developing tools and methodologies for comparing interventions, legislation,
strategies and policies in the EU (including cost-effectiveness evaluation)
Collecting and analysing drug-related legal information
Mechanism for the implementation of the joint action 
on new synthetic drugs
Information exchange
The adoption of the joint action on new synthetic drugs in 1997 provided the
EMCDDA and Europol with a clear mandate to coordinate, via their respective
networks, the collection and exchange of information on any new synthetic sub-
stance appearing on the European market.
In March 2000, the EMCDDA and Europol prepared two joint progress reports,
which provided preliminary information on the substances GHB (gamma-hydroxy-
butyric acid) and ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone)
and which had been collected and exchanged under Article 3 of the joint action
(information exchange). Europol covered the production and trafficking aspects of
the drugs while the EMCDDA looked at use and the possible health and social 
Chapter 4: National and Community strategies
39
risks of the substances. This work was carried out in response to a request from the
Horizontal Working Party on Drugs (HWPD) of the Council of the EU due to the
detection of problematic use of the substances within the EU.
On 20 March, the joint reports were submitted to the Chairperson of the HWPD of
the Council, the Council Secretariat and the European Commission for considera-
tion. On 17 April, the Portuguese Presidency of the EU formally referred GHB and
ketamine to the EMCDDA and Europol for risk assessment under Article 4 of the
agreement.
Risk assessment
The Scientific Committee’s subcommittee on risk assessment met five times in
2000 (see Chapter 7). The work of the subcommittee largely focused on weighting
criteria via the use of a scoring instrument with the purpose of improving the
Guidelines for the risk assessment of new synthetic drugs. In order to advance the
process, the Scientific Committee recommended that MDMA (3,4-methylenedioxy-
N-methylamphetamine) be used as the reference substance to validate the scoring
instrument (see Chapter 7).
On 13 and 14 July, a technical expert group on the pharmacotoxicology of GHB
and ketamine met at the EMCDDA. Discussions were based on the scientific liter-
ature, on the substances and on their current incidences. A literature review —
compiled externally — was submitted to the risk-assessment meetings on 25 and
26 September (see below). This was included in the technical annexes to the final
risk-assessment reports on GHB and ketamine in accordance with the Guidelines
for the risk assessment of new synthetic drugs.
From 25 to 26 September, a formal risk assessment of the drugs was carried out by
the EMCDDA Scientific Committee and experts in Lisbon (see Chapter 7). These
special risk-assessment sessions examined the health and social risks of the sub-
stances and the possible consequences of prohibition. The result was the adoption
of the risk-assessment reports on GHB and ketamine in the framework of the joint
action on new synthetic drugs.
The risk-assessment meeting took note of the significant therapeutic use of keta-
mine as well as the main risks of its recreational use (the psychological depend-
ence, loss of self-control, and the risk of acute intoxication). Therefore, the meet-
ing expressed two different opinions on possible methods of control. The opinion
which received significant support was that, as a common minimum, ketamine
should be subject to control under medicines legislation in the Member States due
to the large legitimate use of ketamine for veterinary medicine. However, another
opinion firmly expressed was that, in addition to medicines legislation, stronger
measures of control were necessary to deal with diversion, trafficking and inadver-
tent exposure (i.e. through fake ‘ecstasy’ tablets). With regard to GHB, the meeting
noted its therapeutic potential as well as the fact that, in recreational use, the dose
margin between the desired and the serious adverse effects is very narrow. Because
of the effects of the drug, the levels of fatal and non-fatal emergencies and reports
of dependency, GHB is considered to pose significant risks to health. As in the case
with ketamine, two opinions were expressed on how GHB should be controlled:
some participants were of the opinion that control through medicines legislation
was sufficient, while many others felt that this substance should be subject to more
stringent control measures.
The reports also contained a number of recommendations made by the meeting
such as the need to target information on the substances to the most vulnerable risk
groups, existing and potential users as well as to key professional groups.
Control
The abovementioned risk-assessment reports on GHB and ketamine were for-
warded to the French Presidency of the HWPD of the Council, to the Secretary-
General of the Council and to the European Commission on 13 October in 
accordance with Article 5 of the joint action (procedures for bringing specific
new synthetic drugs under control). On 22 November, in accordance with 
Article 5 of the joint action, the European Commission submitted its opinion to
the Council. With reference to the Commission’s opinion and to the reports, 
the Presidency put forward draft conclusions at the HWPD meeting on 18 
December. The final conclusions are expected at the beginning of 2001 under
the Swedish Presidency.
The risk assessments on GHB and ketamine were the third and fourth such exer-
cise undertaken to date by the EMCDDA, the first involving MBDB (N-methyl-1-
(1,3-benzodioxol-5-yl)-2-butamine), the second involving 4-MTA (4-methylthioam-
phetamine).
Joint action on new synthetic drugs and the Reitox network
In 2000, the national focal points of the Reitox network regularly informed on
progress, on the functioning of the mechanisms at national level for information
collection and exchange, and on the detection of new substances within the EU.
On 11 July, the EMCDDA released an urgent information briefing through the
Reitox network regarding ‘ecstasy’ tablets and capsules containing very high doses
of MDMA. These had been detected in Belgium and France before the summer.
On 19 July, the EMCDDA released a second alert through the Reitox network
regarding the presence of paramethoxyamphetamine (PMA) in ‘ecstasy’ tablets 
carrying a Mitsubishi logo, seized in Denmark in June.
Cooperation in the field of new synthetic drugs 
and legal information
Cooperation under the joint action on new synthetic drugs
Practical cooperation between the EMCDDA, Europol, the European Commission
and the EMEA was enhanced in 2000.
Cooperation in the field of legal information
During 2000, the EMCDDA and the United Nations International Drug Control
Programme (UNDCP) improved collaboration in their respective database projects
and in the assessment of ‘model of laws’ in the demand-reduction area.
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Collecting and analysing drug-related legal information
National strategies and legislative area
The procedures launched in 1999 to set up a legal information system on drugs
were followed through in 2000 with the implementation of the project to con-
struct the legal database infrastructure (successfully completed in November) and
the setting up of a group of legal correspondents. The first meeting of legal cor-
respondents successfully launched the basis for data-collection procedures on
drug laws.
Two studies, coordinated by the EMCDDA, explored the application of penal and
administrative measures towards drug users and the costs of drug policy in the EU
Member States. The results of the first study were presented in December at the
Council’s Horizontal Working Party on Drugs in Brussels. Another study examining
the legal boundaries of treatment and rehabilitation measures in the EU was
launched in October.
In 2000, the EMCDDA increased its capacity to respond to various institutional
questions as well as those from researchers, students and the media. In September,
the EMCDDA web site was extended with a comprehensive section on legal issues
including drug law tables and comparisons (http://www.emcdda.org/activities/strat-
egy.shtml). The objective is to serve policy-makers and a broad public interested in
the legislative figures and information of EU members. Ad hoc reports as well as
interviews and responses were delivered throughout the year. The contribution to
the Annual report this year included the new trends in drug policy and legislation,
and a key topic on law-enforcement prosecution.
Studies and reports, 2000
National and Community strategies
New synthetic drugs
• ‘EMCDDA–Europol progress report on GHB’ in accordance with Article 3
of the joint action on new synthetic drugs of 16 June 1997
• ‘EMCDDA–Europol progress report on ketamine’ in accordance with Arti-
cle 3 of the joint action on new synthetic drugs of 16 June 1997
• Elliott, S., ‘Review of the pharmacotoxicological data on GHB’
• van Aerts, L. A. G. J. M., and van der Laan, J. W., ‘Review of the pharma-
cotoxicological data on ketamine’
• ‘Report on the risk assessment of GHB in the framework of the joint action
on new synthetic drugs’
• ‘Report on the risk assessment of ketamine in the framework of the joint
action on new synthetic drugs’
Legal information
• Opinion on the project of law in Portugal for the Portuguese Government
• Report on approximation of drug legislation for the Home Office, UK
• Report on legal aspects of substitution treatment for the Pompidou Group
• Report on the situation of penal aspects of drug consumption in the EU —
MILDT, France
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Major meetings organised by the EMCDDA, 2000
National and Community strategies
Date Place Event
New synthetic drugs
16 March EMCDDA Subcommittee on risk assessment 
13–14 July EMCDDA Technical expert and subcommittee on risk
assessment meeting (GHB and ketamine)
24 September EMCDDA Subcommittee on risk assessment
25–26 September EMCDDA Special risk-assessment meetings (extended
EMCDDA Scientific Committee)
26 September EMCDDA Subcommittee on risk assessment
12 December EMCDDA Subcommittee on risk assessment 
Legal information
25 January EMCDDA Public expenditure study — project
assessment
23 February EMCDDA Setting up the European legal database on
drugs (ELDD) — project assessment
27 April EMCDDA Implementation of the memorandum of
understanding with UNDCP on legal
information
15 May EMCDDA Public expenditure study — project
assessment
25–26 May EMCDDA Legal correspondents meeting
27 July EMCDDA Setting up ELDD — project assessment
12 September EMCDDA Study on prosecution of drug users —
project assessment
9 October EMCDDA Setting up ELDD — project assessment
• Comparison of drug law of EU countries — Drug Report to the Italian 
Parliament
• Opinion on Mexican drug law — Ministry of Health, Mexico
• Country profiles on cannabis data and policy situation in the EU for Home
Office, UK
• ‘Prosecution of drug users in Europe: varying pathways to similar 
objectives’
• ‘Public expenditure on drugs in the EU’
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Major meetings attended by the EMCDDA, 2000
National and Community strategies
Date Place Event
New synthetic drugs
January–December Brussels Meetings of the Horizontal Working
Party on Drugs under the Portuguese
and French Presidencies (see Chapter 8)
28–29 February Brussels Second interinstitutional conference on
drugs policy
14 March Paris TREND–Sintes project
10–11 April Monaghan Oisín conference on combating the
potential threat of the abuse of
controlled drugs in rural areas —
synthetic drugs
11 April Brussels Meeting of the EU–Ukraine
subcommittee on drug trafficking —
synthetic drugs
5–6 October Moscow Third meeting of the EU–Russia
subcommittee — synthetic drugs
9 October Paris OFDT meeting on the early-warning
system 
23–24 October Turin Intoxicating substance strategy seminar
25–26 October Estoril Oisín conference on synthetic drugs 
9 November Lisbon Third seminar of magistrates of southern
Europe on drugs
24 November Paris Second European meeting on drug abuse
and dependence
Legal information
21–22 February Strasbourg Social cost meeting
28–29 February Brussels Second conference on drug policy
5 April Luxembourg Legal database assessment meeting
26 June Milan Seminar on social communication on
drugs
13–14 September Kromeritz Training seminar for law enforcement
authorities
28 September Rome Seminar on analysis of drug-related data
4 October Lisbon Seminar on legislative harmonisation on
drugs in the Andean countries
12–13 October Sintra Inter-ministerial conference on harm
reduction
26–27 October S. Patrignano Sixth Rainbow meeting
20 November Brussels Legal aspects of treatment and
rehabilitation measures in the EU —
feasibility study meeting
28–30 November Genoa Third national conference on drugs

The information strategies and communication resources department
encompasses online and off-line publications, media and public relations,
documentation and information technology (IT). In 2000, the EMCDDA’s
work in these fields corresponded primarily to priority objective 4 of the
1998–2000 work programme.
Strategic developments included drawing up a dissemination and
communication strategy to ensure that the needs of target groups,
redefined during 2000, are served and that appropriate products are
produced. The role of IT and its positioning in the Centre was reviewed
and its future defined with the help of an IT strategy group.
The EMCDDA public web site was further developed with the introduction
of a multilingual branch and the integration of online products and
databases resulting from EMCDDA projects. It was highly commended in
the European Information Association awards and praised by the judges
for its genuinely useful content and clear brand image.
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Overview of how the activities described in this chapter relate to the
priority objectives of the 1998–2000 work programme
Priority objective 4
Improving the quality of the Annual report on the state of the drugs problem
in the European Union, the visibility of the work of the EMCDDA and the
Reitox network and the dissemination of the information collected and pro-
duced by the EMCDDA
Strategic developments
EMCDDA publications
Media relations
EMCDDA public web site
EMCDDA intranet
Documentation
Dialogue with the European citizen
Information technology 
Strategic developments
A comprehensive dissemination and communication strategy was drawn up in the
course of the year. This repositions dissemination as the focal point of EMCDDA
activity and lays out a set of measures to be implemented and a range of tailored
products to be developed in order to serve the needs of the Centre’s key audiences
— mainly policy-makers. The EMCDDA reform plan stresses the strategic impor-
tance of online products and future developments in this area were defined in the
2001–03 work programme.
The planned reorganisation of the Centre and new working methods call for a clear
and coherent IT strategy. A working group was established at the end of the year to
work on this issue.
EMCDDA publications
2000 Annual report on the state of the drugs problem 
in the European Union
The 2000 Annual report on the state of the drugs problem in the European Union
was launched by the EMCDDA on 11 October at the European Commission’s
Spokesman Service in Brussels (see ‘Media relations’ below). A special presentation
of the report was made on 10 October to the European Parliament’s Committee on
Citizens’ Freedoms and Rights, Justice and Home Affairs.
The report, targeted primarily at policy-makers, assembles new data and informa-
tion from 1998 while updating findings from previous years. Special effort was
made in 2000 to distil the findings into a more concise report better suited to its
target audience.
The report updates information on overall trends, patterns of drug use, health con-
sequences of drug use and responses to drugs. It also carries special sections on:
the specific problems facing women and drugs; substitution treatment; the prose-
cution of drug-related offences; as well as a special chapter on the state of the
drugs problem in central and eastern Europe.
At the time of the launch, all 11 language versions of the Annual report were
available in printed form, and electronic files were downloadable from the
EMCDDA’s web site. In addition to this, basic epidemiological tables used in its
preparation were made available online. In order to manage increased traffic to
the web site, a supplementary download area was created. Shortly after the
launch the report was proactively distributed to the Centre’s audiences and part-
ners (over 15 000 copies).
Production of other EMCDDA publications
In 2000, the EMCDDA also published its General report of activities 1999; six
issues of its bimonthly newsletter, DrugNet Europe; two titles in its Scientific
Monograph series and one in its Insights series. In total 12 titles and 44 volumes
were published.
Cooperation with the Office for Official Publications of the 
European Communities
In 2000, EUR-OP was responsible for the production and distribution of all
EMCDDA publications with the exception of DrugNet Europe, which is produced
and distributed locally. Contacts with EUR-OP’s ‘Sales and copyright’ division
(OP/A/4), which includes the unit for promotions and fairs, were strengthened dur-
ing the year, and joint ventures undertaken to increase the visibility of the Centre’s
products.
European Union Publishers’ Forum
On 19 October, the EMCDDA was among the guest speakers at the European
Union Publishers’ Forum (EUPF), where it presented the guiding principles of its
publications programme and offered elements of potential interest to commercial
publishers. In the run-up to the meeting, the Centre contacted over 180 commer-
cial publishers in order to introduce its publications and gauge interest in potential
licensing and co-publishing agreements. Partnerships with interested publishing
houses were being followed up at the end of the year.
International exhibitions and fairs
Frankfurt Book Fair
From 18 to 20 October, the EMCDDA attended the 52nd Frankfurt Book Fair, the
largest international trade fair for the publishing world. The Centre participated at
the European Union stand where it displayed its latest publications and general
publicity material on its products. The Centre’s work generated much interest from
those attending the fair.
The EMCDDA produced marketing materials for display in Frankfurt including a
publicity bookmark advertising its recently published Annual report and a cata-
logue of EMCDDA publications, Drugs in Europe, published in cooperation with
EUR-OP (OP/A/4).
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Online Information 2000
From 5 to 7 December, the EMCDDA attended Online Information 2000, the
largest and most comprehensive information-industry event in the world, held in
London. The Centre was among several EU services exhibiting at the European
Union stand.
The EMCDDA distributed information in the conference press dossier and EU press
packs publicising its online activities. The EMCDDA workstation at the stand
received many visitors including representatives of drug-related organisations, aca-
demics, librarians, the media and educational professionals.
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EMCDDA publications, 2000
Title Languages
2000 Annual report on the state of the drugs All 11 EU languages
problem in the European Union 
General report of activities 1999 English, French, German
DrugNet Europe, six issues, 21–26 English, French, German, 
Portuguese
‘Understanding and responding to drug use: English
the role of qualitative research’, Scientific 
Monograph, No 4
‘Evaluation: a key tool for improving drug English
prevention’, Scientific Monograph, No 5
‘Reviewing current practice in drug-substitution English
treatment in the European Union’, Insights, No 3
Drugs in Europe, publications catalogue English, French, German
(EUR-OP–EMCDDA co-production).
Total number of titles 12
Total number of volumes 44
Further information on all EMCDDA publications including details of how to order are avail-
able on the EMCDDA web site at http://www.emcdda.org/publications/publications.shtml
Media relations
The influence of the mass media on the policy-maker and the general public is
undisputed, as is their contribution to raising the visibility of the EMCDDA in Euro-
pean society. The agency therefore considers the media to be a prime conduit of
information to its target audiences and, as such, one that must be properly served.
In 2000, the EMCDDA continued to expand and improve its relations with the
media, to record the results of these contacts, and to enhance communication with
journalists.
Media contacts
Throughout 2000, the EMCDDA’s media desk responded to all incoming media
requests, aiming to provide answers within 24 hours. Details of these contacts
were catalogued and included, for the first time, in the EMCDDA quarterly news
reviews (see ‘Media follow-up’ below).
The EMCDDA continually updated its media contact lists per EU Member State
and selected third countries. It also updated the contacts in its fax database
(designed for automatic dissemination of faxes to 1 250 journalists) and continued
to build up a list of e-mail groupings for the faster transmission of news releases.
These lists cover both print and broadcast media. Contacts with the Brussels press
corps, specialised journals and the youth media were also increased in 2000, 
following the recommendations of an external consultant in 1999. The Centre
maintains close contact with a core group of drug-specialised journalists.
Media products
In 2000, the EMCDDA produced 10 news releases (see http://www.emcdda.org/
press/press.shtml). These releases focused less on institutional events and more on
the Centre’s findings and work results. All news releases were disseminated by fax
and e-mail to over 1 200 journalists across the EU.
As in previous years, the Centre contributed articles on its activities to magazines
and newsletters in the EU and enhanced its profile through listings in major 
directories of international organisations.
Media events
On 11 October, the EMCDDA launched its 2000 Annual report at a news confer-
ence at the Spokesman’s Service of the European Commission in Brussels.
EMCDDA Director, Georges Estievenart, presented the latest findings to the Brus-
sels-based ‘European media’.
The EMCDDA distributed over 1 000 press packs across Europe containing news
releases and the Annual report in 11 EU languages. In 2000, the EMCDDA went a
step further than in previous years by producing two special-focus releases on
women drug users and on substitution treatment in addition to the two main
releases. Thus four news releases in all 11 EU languages were distributed to 1 240
journalists. The Reitox national focal points, Spokesman’s Service and the 
European Commission and Parliament offices in the EU Member States helped 
to further disseminate these communications and to follow up media contacts 
and coverage. The launch was filmed by the European Commission’s audiovisual
service for dissemination to interested European TV networks. The Euronews channel
produced a special programme on the work of the EMCDDA which was broadcast
throughout the week following the launch.
As in previous years, one of the most important features of the launch was the avail-
ability of the Annual report and news releases on the EMCDDA web site, offering
journalists rapid access to materials. On that day helpdesks also operated at the 
EMCDDA and national focal points to answer journalists’questions and give interviews.
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Media follow-up
Throughout 2000, the EMCDDA produced quarterly news reviews recording the
impact of EMCDDA news releases. These also catalogued: press contacts; articles
published by EMCDDA staff in external journals; and book review articles on the
Centre’s products.
As in previous years, the Centre also compiled a news review on the launch of its
2000 Annual report, which totalled some 400 pages.
EMCDDA public web site
The EMCDDA’s public web site, at http://www.emcdda.org, is central to the Cen-
tre’s dissemination strategy. Prioritising the use of Internet technology as a means
of reaching the key audiences also forms an integral part of the Centre’s reform
plan and time has been dedicated to planning future developments in this area.
The site, which was extensively redesigned and restructured in 1999, is gaining
repute in the information field. In March 2000, at the ‘EIA Awards for European
Information Sources 1999’, it was nominated as one of two ‘Commended titles’ in
the ‘Electronic sources: Internet web sites’ categories.
One of the main achievements in 2000 was the integration of a multilingual
branch which now provides a comprehensive overview of the Centre’s work in all
official EU languages. Content developments included the addition of a compre-
hensive section on legal issues concerning drugs.
In the context of the online publication of the Annual report, a new section was
introduced better adapted to the Internet medium, offering downloadable statistical
tables and data sources.
Further measures were also taken to improve the performance and technical sta-
bility of the service. A second download site is now hosted outside the Centre to
ensure stability and ease traffic at peak periods e.g. at the launch of the Annual
report. Promotion and search possibilities were enhanced through increased meta
tagging of files.
The public site is the general interface from which the entire range of the Centre’s
online products and databases can be accessed. The visual integration of the ‘Vir-
tual library’ project and Evaluation Instruments Bank were completed in 2000 and
further products are on course for integration.
EMCDDA intranet
The Centre’s intranet has been expanded and improved. Its profile has been raised
and it has now been adopted as the preferred means of internal communication.
An information correspondent in each department is responsible for providing up-
to-date information and contributing to its further development under the responsi-
bility of the intranet project manager.
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Documentation
Documentation and Information Centre (DIC)
During 2000, the EMCDDA’s documentation collection was expanded. New 
material was catalogued, classified and loaded into the EMCDDA’s internal library
catalogue.
Indexing of the documentary collection commenced so as to render the library
database fully functional and provide users with better access to the information. A
list of terms covering the EMCDDA’s working areas, and organised thematically,
was drawn up to assist in this task. This exercise forms part of a broader terminol-
ogy project covering both documentation and publications.
The ‘Thematic bibliographies’ area was enlarged with the addition of a third bibli-
ography of scientific literature on ‘drug-related non-fatal emergencies’.
Development of ‘Bibliodatabase’
Bibliodatabase, the online bibliographic catalogue available to EMCDDA staff was
improved with new software which provides a user-friendlier interface and offers
more capabilities. Two chapters — ‘EMCDDA reports’ and ‘Thematic biblio-
graphies’ — were made available to the general public via the Centre’s public web
site during 2000.
User services
Internal and external demand for the provision of user services continued to grow.
The work undertaken by the DIC during 2000 covered:
• bibliographic searches on internal and external databases (including Internet
and specialised CD-ROMs);
• strengthening contacts with European and international organisations to acquire
and exchange documents;
• timely replies to information requests;
• lending services and inter-library loans;
• presenting the documentary activities to external visiting groups.
Representation and partnership activities
In 2000, documentation staff participated in the Eurolib general assembly and in
the Elisad annual conference. As a follow-up to these meetings, the EMCDDA
plans to disseminate its documentary resources in the Eurolib directory via the
Europa server and to participate in Elisad projects such as the European Internet
subject gateway on alcohol and other drugs. 
Dialogue with the European citizen
The EMCDDA pursues an active policy in the field of public information and
receives an increasing number of requests for information on its work and findings.
In 2000, this service concentrated on: ensuring a quick and high-quality response;
guaranteeing the appropriate level of response to the audience’s needs; and imple-
menting the code of good administrative behaviour for officials in their relation to
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the public, which was adopted by the Centre in January, following a recommen-
dation by the European Ombudsman in 1999.
Information technology (IT)
Common EMCDDA–Reitox electronic network
The common EMCDDA–Reitox electronic network, set up with funding from the
European Commission’s interchange of data between administrations (IDA) pro-
gramme, was increasingly used by the Reitox community (EMCDDA and national
focal points) for disseminating and exchanging information and promoting under-
standing and transparency within the network (see Chapter 3).
During 2000, a working group of experts, composed of members of the EMCDDA
and the NFPs, was created to discuss the further development of this network
within the framework of the IDA II programme. The submission of the project to
the European Commission has been postponed until 2001 in order that the final
decisions of the internal reform may be taken into account.
Consolidation of the EMCDDA’s IT environment
In 2000, new equipment (e.g. PCs, servers), miscellaneous software packages and
licenses were purchased and maintenance contracts for IT services set up or
renewed. Part of this investment relates to maintaining an up-to-date IT environ-
ment necessary for the daily work of EMCDDA staff who continued to receive per-
manent technical assistance from the internal helpdesk.
The other part relates to building the necessary IT environment for the Centre’s vari-
ous information systems and databases (e.g. EDDRA, Reitox site). This included the
integration of a high availability firewall system to ensure security in the exchange of
data between the EMCDDA and the Internet. A dedicated telecommunication line
(256Kbps bandwidth) between the EMCDDA and the TESTA II network (a trans-Euro-
pean data communication network that links the European institutions, agencies and
the Member States) was also installed. Simultaneously, the capacity of the current
telecommunication line that links the EMCDDA to the Internet has been increased to
a bandwidth of 256Kbps. Increasing the capacity of the Internet connection has en-
hanced access to the EMCDDA public web site and to the Reitox web site (both
hosted at the Centre) for external and internal users alike. The web site on Phare’s
multi-beneficiary drugs programme (http://www.fad.phare.org) was transferred to the
IT environment of the Centre.
In April, the Court of Auditors of the European institutions carried out a first audit
on the information technology (IT) environment as well as on the budgetary and
accounting software system (SI2) of the EMCDDA. The Centre’s budgetary and
accounting software system (SI2) has since been set up to enable the EMCDDA
financial controller in Brussels (European Commission) to consult the database via
a special telecommunication line.
In November, an information technology strategy working group was set up to dis-
cuss the role and positioning of IT in the overall EMCDDA strategy. The group is
composed of some of the Centre’s staff as well as external participants (e.g. repre-
sentatives from the European Commission and the NFPs).
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Project advice and participation
IT team members continued to play an important role as technical advisers and/or
project leaders for many EMCDDA projects involving software development, or as
consultants on projects concerning IT infrastructure. These projects include:
• the exchange on drug demand-reduction action (EDDRA) information system
(see Chapter 2);
• the information system on training activities in the field of demand reduction
(ISTRA);
• the Evaluation Instrument Bank (EIB) (see Chapter 2);
• the budgetary and financial system (SI2);
• the EMCDDA public web site;
• the Reitox web site;
• the EMCDDA intranet;
• the web interface for the Centre’s library catalogue;
• the ‘Virtual library’ system;
• the development of a legal database on drugs (ELDD);
• the Centre’s mail management system (Adonis);
• TESTA and TESTA II;
• the flexitime system (Teleponto);
• the inventory information system (ELS);
• the preparation of the epidemiology information system;
• IDA II;
• the European web site and network for qualitative research
(http://www.qed.org.uk).
Chapter 5: Information strategies and communication resources
53
Major meetings organised by the EMCDDA, 2000
Information strategies and communication resources
Date Place Event
Media relations
11 October Brussels Launch of the 2000 Annual report on the state
of the drugs problem in the European Union,
European Commission Spokesman’s Service.
Major meetings attended by the EMCDDA, 2000
Information strategies and communication resources
Date Place Event
Documentation
16–17 October Thessaloniki Eurolib interim meeting, Cedefop 
9–11 November Prague Elisad 12th annual meeting: ’Linking
together’, National Institute of Public
Health
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Articles published, 2000
Information strategies and communication resources
Media relations
Robertson, K., ‘EU drugs agency presents new web site’, The Parliament Mag-
azine, No 17, January 2000, p. 16.
Robertson, K., ‘Presentation of the publications programme of the European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA)’, European
Union Publishers’ Forum Newsletter, No 1, 2000, pp. 8–9.
Robertson, K., ‘Providing information you can count on: European Monitoring
Centre for Drugs and Drug Addiction’, Frontier Free Europe, No 3, 2000, Sup-
plement, pp. 1–2, European Commission.
Publications and web site
20 January Luxembourg Meeting with ERIN on web site project
5 July Dublin Working visit to the EU agency, the
European Foundation for the Improvement
of Living and Working Conditions
13 September Luxembourg Meeting with ERIN on web site project
17–20 October Frankfurt Frankfurt Book Fair
5–7 December London Online Information 2000
Information technology
12–13 January Brussels IDA–TESTA user group meeting and IDA
inter-service group meeting
16–17 February Brussels IDA–TESTA tutorial and workshop on
MPLS tag-switching technology
18 February Brussels SI2: CSS steering committee meeting
23–28 February Hannover CeBIT Fair — European exhibition for IT
professionals
14–16 June Brussels Feasibility study meeting on SI2 in the
context of TESTA II
27–29 June Brussels TESTA meeting and SI2 CSS steering
committee meeting
17–18 July Brussels Preparation of IDA EMCDDA–Reitox II
project
27 July Luxembourg SI2: information exchange on business
objects
25–29 September Brussels SI2: training course in business objects
9–10 November Brussels SI2: steering committee meeting
21 November Lisbon Information technology strategy working
group meeting
23 November Brussels IDA meeting of national experts on portals
Further to the findings of the EMCDDA external evaluation carried out in
the second half of 1999 (3) attention was focused on reform. This took the
shape of a reform plan that was prepared by the EMCDDA Director and
adopted by the EMCDDA Management Board in September 2000.
This plan aims to reform the EMCDDA internal structure and working
methods. Among other measures, it defines the EMCDDA’s approach to
quality management, project-based planning and activity-based budgeting
and management and outlines the EMCDDA’s human resources policy 
for the coming years.
Chapter 6
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(3) Management consultants Deloitte & Touche embarked on the external evaluation of the Centre in July 1999 fol-
lowing a call for tender launched by the European Commission earlier in the year.
Administration
EMCDDA staff
Three new posts were created under the 2000 budget: one post at A7/A6 level, one
at B5/B4 level and one at C5/C4 level. At the end of 2000, a total of 52 statutory
staff members (3 European Union officials, 44 temporary agents, 4 auxiliary agents
and 1 seconded national expert) were employed at the EMCDDA along with 13
local agents. The table below indicates the nationality, status and grade of the staff
members.
Employees of the EMCDDA share the same status as their colleagues in other Euro-
pean Community agencies, being subject to the ‘Staff regulations and rules appli-
cable to officials and other servants of the European Communities.’
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EMCDDA staff breakdown by nationality, status and grade 
Nationality EU Temporary Auxiliary Seconded  Local Total
officials staff staff national agents
experts
A B C A B C A B C A B C
Belgium 1 1 3 2 2 2 11
Denmark 1 1
Germany 3 1 1 1 6
Greece 1 1
Spain 1 3 1 1 6
France 4 3 7
Ireland 0
Italy 3 1 4
Luxembourg 1 1
Netherlands 1 1
Austria 0
Portugal 1 4 1 4 11 21
Finland 0
Sweden 1 1 2
United 4 4
Kingdom
Total 2 1 0 24 11 9 0 1 3 1 0 0 13 65
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Finance
Key decisions
In 2000, key financial decisions taken by the EMCDDA Management Board
included:
• a decision to offer the Director discharge on the implementation of the 1998
budget;
• the adoption of the 2000 budget of EUR 8 250 000;
• the adoption of the EMCDDA’s 2001 preliminary draft budget of EUR
8 750 000.
EMCDDA 2000 budget
The budgetary figures for 2000 are presented in the tables below.
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Budgetary provisions and appropriations, 2000
Title Description EUR
1. Expenditure relating to persons working with the office 
• Staff in active employment 3 777 000
• Missions and duty travel 230 000
• Other staff-related expenditure (socio-medical 
infrastructure, exchange of officials, etc.) 58 000
Total under Title 1 4 065 000
2. Buildings, equipment and sundry operating expenditure
• Investment in immovable property, rental of buildings 
and associated costs 175 000
• Data processing 200 000
• Movable property and associated costs 250 000
• Current administrative expenditure 113 000
• Postal charges and telecommunications 127 000
• Statutory meetings 170 000
Total under Title 2 1 035 000
3. Expenditure resulting from special functions carried out by the
institution
• Expenditure on formal and other meetings 235 000
• Studies, surveys, consultations 470 000
• Publishing 725 000
• European network on drugs and drug addiction (Reitox) 1 720 000
Total under Title 3 3 150 000
Total core budget 8 250 000
4. Expenditure relating to other subsidies
• EC financing of specific projects p.m.
• Phare financing for implementing pre-accession strategy p.m.
10. Other expenses (reserve) 0
Total budget 8 250 000
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Execution of the budget: Credit consumption, 2000
(Commitments)
Title Description Consumption of 
available credits 
(%)
1. Staff
• Staff salaries, allowances, missions, etc. 98
2. Buildings, equipment and sundry operating expenditure 99
3. Operating expenditure 95
4. Expenditure relating to other subsidies 0
Total consumption (Titles 1, 2, 3 and 4) 97
EMCDDA balance sheet for the financial years
1999 and 1998: Assets
(1 000 EUR)
Assets 1999 1998
Fixed assets
• Fixed assets 3 603 3 518
Subtotal 3 603 3 518
Stocks
• Office equipment 17 29 
Subtotal 17 29 
Current assets
• Commission subsidy 0 570
• Specific grants 265 0
• VAT to be recovered 3 4
• Sundry debtors 37 403
• Payments on specific subsidies 1 10
Subtotal 306 987 
Cash accounts
• Bank 4 276 3 230 
• Imprest account 49 527
• Transfers in progress – 20 – 47
Subtotal 4 305 3 710
Total assets 8 231 8 244 
EMCDDA balance sheet for the financial years
1999 and 1998: Liabilities
(1 000 EUR)
Liabilities 1999 1998
Fixed capital
• Own capital (4) 3 620 3 547
• Balance for the financial year 1 617 1 287 
Subtotal 5 237 4 834 
Current liabilities
• Commission subsidy 0 570
• Specific grants 265 0
• VAT to be recovered 3 4
• Sundry account due 150 405
• Automatic carry-overs of 
appropriations 2 133 2 112
• Non-automatic carry-overs 
of appropriations 280 280
• Re-use accounts 163 39
Subtotal 2 994 3 410 
Total liabilities 8 231 8 244
(4) The amount corresponds to that of fixed assets and stocks excluding the refurbishing of the building (about EUR
1 million).
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Out-turn account
Revenue and expenditure for the financial years 1999 and 1998 
(1 000 EUR)
1999 1998
Revenue
• EC subsidy 8 156 9 695
• Miscellaneous revenue 0 277 
Total revenue 8 156 9 972
Expenditure 
• Title I: Staff expenditure
— Payments 3 367 2 751 
— Automatic carry-overs of appropriations 59 138 
• Title II: Buildings, equipment and miscellaneous 
administrative expenditure
— Payments 637 805
— Automatic carry-overs of appropriations 240 430
— Non-automatic carry-overs of appropriations 205 0
• Title III: Operating expenditure 
— Payments 1 569 1 305
— Automatic carry-overs of appropriations 1 833 1 544
— Non-automatic carry-overs of appropriations 75 280 
Total revenue 7 985 7 253 
Out-turn for the financial year 
• Budgetary out-turn 171 2 719
• Cancelled appropriations 159 137 
• Balance carried over from the previous year 1 287 – 1 569
Balance for the financial year 1 617 1 287 
The EMCDDA’s statutory bodies are the Management Board, the Bureau of
the Management Board and the Scientific Committee, all of which met in
2000. A summary of the decisions adopted and major points discussed at
their meetings are set out in the following pages.
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Management Board
The Management Board is the main decision-making body of the EMCDDA. It
meets at least once a year and consists of one representative of each Member State
of the European Union, two representatives of the European Commission and 
two persons highly qualified in the field of drugs designated by the European 
Parliament.
In 2000, the Management Board met three times in Lisbon. Besides its usual
agenda items — such as the adoption of the annual work programme and budget
— it adopted the medium-term perspectives and objectives of the Centre and an
internal reform plan, both of which were drawn up following the external evalua-
tion of the EMCDDA. The committee met on all three occasions under the chair-
manship of Franz J. Bindert (Germany).
Management Board meetings in 2000
At its 18th meeting in Lisbon on 12 to 14 January, the Management Board adopted,
among others: the 2000 work programme; the General report of activities 1999; a
budget of EUR 8.25 million for 2000; and a preliminary draft budget of EUR 8.75
million for 2001. In the context of the implementation of the legal information sys-
tem, the Board also decided to launch a study on substitution treatment. The Board
gave discharge to the Director for the implementation of the 1998 budget and
decided to carry over EUR 279 564 from 1999 to 2000. It further adopted a docu-
ment on relations with international organisations and mandated the Director to
draw up a ‘Code of good administrative behaviour for officials in their relations
with the public’.
In addition to these decisions, the Management Board discussed the accession of
the candidate countries and the EMCDDA media strategy.
At its 19th meeting of 3 March, the Management Board discussed in depth the
report drawn up by external consultants on the EMCDDA’s activities. The Manage-
ment Board took several decisions to improve the working methods and the organ-
isation of the Board. It requested the Director to present concrete proposals for the
reorganisation of the internal structure and to conduct a fundamental analysis on
ways of improving the use of the network as well as the organisation of and sup-
port for the national focal points. The Board also decided to set up a small work-
ing group to propose solutions for the internal and structural problems posed by
the EMCDDA’s forthcoming enlargement.
At its 20th meeting from 6 to 8 September, the Management Board adopted the new
rules of procedure of the Board, the medium-term perspectives and objectives of the
Centre, the internal reform plan and a document on the enlargement strategy.
In addition to these decisions, items discussed included: the 2001–03 work pro-
gramme; the 2001 work programme; reporting to the UNDCP; and Iceland’s inter-
est in participating in the activities of the EMCDDA.
Bureau
The Bureau of the Management Board meets five to six weeks before each Manage-
ment Board meeting to prepare the agenda for the latter in consultation with the 
Director. In accordance with Article 2 of the rules of procedure of the Management
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Board, the Bureau may also, between any two meetings of the Board and in con-
sultation with the Director, take decisions unanimously which are urgent or neces-
sary for the management of the Centre, subject to ratification by the Board at its next
meeting. In 2000, the Bureau met twice in Lisbon and five times in Brussels (5).
Bureau meetings in 2000
In the course of the year, issues discussed by the Bureau included: the external
evaluation of the Centre and the work of the special EMCDDA steering group set
up to accompany the evaluators; the limitations and suitability of the current
EMCDDA headquarters; the launch of the 2000 Annual report; and the timetable
for the production of the 2001 Annual report.
Scientific Committee
The Scientific Committee is a consultative organ that assists the Management
Board and the EMCDDA with its opinions and recommendations on scientific mat-
ters. The committee consists of one representative from each of the Member States
of the European Union, although the Management Board may elect up to six other
members. The committee is convened by its chairman at least once a year.
In 2000, the Scientific Committee met four times in Lisbon, holding two regular
meetings and two extended meetings in the framework of the joint action on new
synthetic drugs. The committee met on all four occasions under the chairmanship
of Desmond Corrigan (Ireland). 
Scientific Committee meetings in 2000
At the 13th meeting of the EMCDDA Scientific Committee, 16 to 17 March, in-
depth discussions were held on the findings of two evaluation exercises carried out
in 1999: the external evaluation of the EMCDDA; and a technical evaluation study
on the mechanisms set up to implement the joint action on new synthetic drugs,
undertaken by the Belgian national focal point.
As a follow-up to these two exercises, the committee delivered formal opinions
with a number of operational recommendations for improving its work, including
the development of task-specific subcommittees. Meetings also took place of the
subcommittees on the quality indicators for epidemiological and demand-
reduction studies. Among others, concrete scientific criteria for projects and reports
were discussed and the importance of publication in scientific peer-review journals
was stressed. The committee accepted the proposal from the steering group on
new synthetic drugs that its name should be changed to ‘subcommittee on risk
assessment’ for reasons of consistency. Furthermore, it discussed the findings of the
subcommittee’s meeting on the development of the Guidelines for the risk assess-
ment of new synthetic drugs (see below). Updated information was presented at
the meeting on GHB and ketamine and on the follow-up to the risk-assessment
report on 4-MTA.
On 25 and 26 September, an enlarged EMCDDA Scientific Committee met to
assess the risks of GHB and ketamine. These special risk-assessment meetings were
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(5) 10 January (Brussels); 21 February (Brussels); 3 March (Lisbon); 29–30 June (Brussels); 28 July (Brussels); 
6 September (Lisbon); 27 November (Brussels).
attended by Scientific Committee members, additional experts from the Member
States, representatives of the European Commission, the European Agency for the
Evaluation of Medicinal Products (EMEA) and Europol. The enlarged committee’s
tasks were to assess the health and social risks and possible consequences of pro-
hibition of the substances. The meetings resulted in the adoption of the risk-assess-
ment reports on GHB and ketamine. The reports were submitted on 13 October to
the Council of the EU and the European Commission for further consideration in
accordance with Article 5 of the joint action (see Chapter 4).
The 14th meeting of the EMCDDA Scientific Committee took place on 11 to 12
December and examined, discussed and adopted an opinion on the EMCDDA’s
2001 and 2001–03 (draft) work programmes. The Scientific Committee strongly
endorsed the view that the EMCDDA continue to be promoted as a ‘centre of
excellence’ among drug experts, researchers and practitioners by producing infor-
mation of a high scientific standard. The Scientific Committee also examined, dis-
cussed and formally approved the recommended draft technical tools and guide-
lines for the implementation of the five key epidemiological indicators by Member
States. One of the recommendations of the committee was that these indicators be
implemented on a widespread basis within the EU. Among the other items dis-
cussed at the meeting were the medium-term perspectives for the Centre and the
EMCDDA internal reform plan and its effects on the Scientific Committee. The Sci-
entific Committee also commented on the Centre’s 2000 Annual report. Finally, the
committee received updated information on the follow-up of the risk-assessment
reports on GHB and ketamine.
Subcommittee on risk assessment meetings
The Scientific Committee’s subcommittee on risk assessment — set up in 1997 to
prepare the risk-assessment procedure under the joint action on new synthetic
drugs — met five times in 2000 (see also Chapter 4) (6).
On 16 March, the subcommittee on risk assessment further developed its Guide-
lines for the risk assessment of new synthetic drugs. In this area, progress was made
on the process of weighting and scoring criteria via the use of a scoring table. The
subcommittee recommended that MDMA be used as the reference substance to
validate this scoring instrument. Accordingly, it was recommended that the Centre
commission a study to prepare the relevant technical annexes to the guidelines on
MDMA. The outcome of the action on compiling a shortlist of laboratories for tox-
icity testing within the EU, which had been proposed at the risk-assessment meet-
ing on MBDB of 9 and 10 November 1998, was also presented.
On 13 and 14 July, a technical expert meeting on the pharmacotoxicology of GHB
and ketamine was held at the EMCDDA and attended by experts and members of
the subcommittee on risk assessment. A scientific literature review on the sub-
stances was presented.
The meeting on 24 September prepared the extended Scientific Committee meet-
ings on GHB and ketamine, whereas the meeting on 26 September finalised the
risk-assessment reports on GHB and ketamine in the framework of the joint action
on new synthetic drugs.
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(6) 16 March, 13 and 14 July, 24 and 26 September.
Since its creation, the EMCDDA has developed partnerships with a wide
range of organisations, both within the European Union and further afield.
In 2000, the Centre furthered existing cooperation while establishing links
with new bodies and regions.
The Executive Director, Georges Estievenart, signed memoranda of
understanding (MOU) with the World Health Organisation (WHO) and the
Inter-American Drug Abuse Control Commission of the Organisation of
American States (CICAD-OAS). These were in addition to those already
signed and implemented with the United Nations Drug Control Programme
(UNDCP) and Council of Europe’s Pompidou Group. Contacts were also
taken up with Europol, Interpol and the World Customs Organisation
(WCO), with a view to agreeing the contents of other MOUs.
The Centre received many visits from authorities in third countries such
as from Bolivia, Japan and Mexico, and from other international bodies,
such as the International Narcotics Control Board (INCB). It was a special
honour for the EMCDDA to receive the visit of their Royal Highnesses the
then Hereditary Grand Duke and Duchess of Luxembourg.
In the margins of the ministerial conference of the Pompidou Group,
ministers from various candidate countries, such as Hungary, Poland and
Turkey visited the Centre. These visits allowed for deeper discussion on
the future participation of candidate countries in the Centre’s activities.
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Overview of how the activities described in this chapter relate to the
priority objectives of the 1998–2000 work programme
Priority objective 5
Developing structured cooperation with the EMCDDA’s international partners
and ensuring synergies and complementarity with EU programmes and activ-
ities, avoiding any duplication of work
Cooperation with European Union institutions and bodies
Cooperation with European and international partners
Cooperation with central and east European countries (CEECs)
Developing cooperation with third countries
Cooperation with European Union institutions and bodies
European Parliament
In 2000, the EMCDDA followed discussions in the European Parliament regarding
the EU drug phenomenon. In October, the Centre presented the EMCDDA reform
plan and medium-term perspectives to the Committee on Citizens’ Freedoms and
Rights, Justice and Home Affairs which were positively received. A special present-
ation was also made of the 2000 Annual report prior to its official launch on 11
October.
Council of the European Union
In 2000, the EMCDDA participated as an expert body, along with Europol, in all
meetings of the Horizontal Working Party on Drugs (HWPD) of the Council of the
European Union. During the Portuguese Presidency, the Centre played an active
role, alongside the Commission and Europol, in the preparation of the EU action
plan on drugs (2000–04). The EMCDDA was involved in several meetings, in par-
ticular on the prevention of drug-related crime, organised in Portugal under the
auspices of the Presidency of the EU. The Centre was also present in the Lisbon
high-level meeting for the launch of the ‘Coordination and cooperation mechanism
between the EU, Latin America and the Caribbean’ in the framework of the action
plan endorsed by the Rio Summit of June 1999.
At the request of the French Presidency of the EU, the EMCDDA presented to the
HWPD the state of achievement of draft definitions and guidelines drawn up by
the Centre for the implementation in Member States of the five key epidemiolog-
ical indicators. The EMCDDA also participated in the ad hoc meetings of the
HWPD to study the French proposal to network the existing structures, including
the Reitox national focal points, in order to obtain better information-collection
and evaluation of new trends and behaviours of drug use and their associated
risks. On the same subject, the Centre participated actively in the European 
seminar held in Paris on 23 to 24 November under the auspices of the French
Presidency. As requested by the Centre’s regulation, a draft proposal of the 
EMCDDA three-year work programme 2001–03 was sent to the Council, as well
as to the Commission, to seek their opinion before adoption by the Centre’s Man-
agement Board.
European Commission
Cooperation with various sections of the European Commission was intensified, in
particular with the Directorate-General for Justice and Home Affairs.
Cooperation is highlighted throughout this report under the respective activity area.
Directorate-General for Justice and Home Affairs: cooperation in the preparation
and launch of the 2000 Annual report.
Spokesman’s Service of the European Commission: hosting of the 2000 Annual
report press launch and news conference (see Chapter 5).
Directorate-General for Enterprise: interchange of data between administrators
(IDA) programme (see Chapter 5).
Directorate-General for Health and Consumer Protection: programme for the pre-
vention of drug dependence (see Chapter 2).
Directorate-General for Research: the EMCDDA received funding from the Euro-
pean Commission’s targeted socioeconomic research (TSER) programme for a num-
ber of projects in the field of epidemiology (see Chapter 1).
Eurostat: The EMCDDA cooperated closely on the topic of drug-related deaths (see
Chapter 1).
European Union agencies
The EMCDDA participated in several meetings of the EU decentralised agencies,
and contributed to discussions on the impact of the future participation of the can-
didate CEECs on their work.
Cooperation with European and international partners
Council of Europe cooperation group to combat drug abuse and
illicit trafficking (Pompidou Group)
Following the implementation of the memorandum of understanding signed on 28
September 1999 between the Council of Europe (Pompidou Group) and the 
Centre, the EMCDDA participated in the 45th, 46th and 47th permanent corre-
spondents meetings. The EMCDDA also participated in the ministerial conference
in Sintra on 12 to 13 October 2000. On this occasion the EMCDDA submitted a
written contribution to the participants’ pack — ‘Reviewing legal aspects of substi-
tution treatment at international level’. In addition to these activities, other joint
projects are under discussion including one on the specific problems of women
and drugs, and a study on social costs.
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United Nations International Drug Control Programme (UNDCP)
The EMCDDA attended the last Commission on Narcotics Drugs (CND) held in
Vienna 6 to 10 March 2000. A meeting, attended by representatives from most of
the international organisations and interested countries, was held prior to this at
EMCDDA headquarters with a view to identifying a core set of harmonised indica-
tors in the epidemiology field. The results of this meeting were submitted to the
CND in the so-called ‘Lisbon consensus document’. A number of interesting joint
topics were identified, among them, the future establishment of a joint legal infor-
mation system, the identification of criteria to avoid overlap and duplication of
work in the compilation of national reports, and the implementation of the main
elements of the abovementioned document.
World Health Organisation (WHO)
In late March, the memorandum of understanding between both organisations was
signed through an exchange of letters between Mr Marc Danzon, Director of
WHO regional office for Europe and Mr Georges Estievenart, EMCDDA Executive
Director. Preliminary discussions have taken place to identify joint projects for its
future implementation. Among the different possibilities is a joint project related to
drug abuse in prisons.
European Police Office (Europol)
Cooperation between the EMCDDA and Europol was enhanced in 2000 due to
their shared role in the joint action on new synthetic drugs (see Chapter 4).
International Criminal Police Organisation (Interpol)
Preliminary discussions between officials from both organisations resulted in the
drafting of a memorandum of understanding. A document identifying possible
activities to be jointly developed was also drawn up and was due to be approved
by the Management Board in early 2001, prior to final approval by the Interpol
General Assembly. The EMCDDA attended as an observer the last Interpol General
Assembly held in Rhodes from 30 October to 4 November.
Inter-American Drug Abuse Control Commission (CICAD)
The EMCDDA attended as an observer the 28th CICAD regular meeting held in
Port-of-Spain from 24 to 26 October, following the signing of the memorandum of
understanding agreed by both organisations through an exchange of letters in July.
The EMCDDA also attended the 27th CICAD regular meeting held in Washington
from 1 to 3 May 2000. In the margins of this meeting, members of CICAD who par-
ticipated in the preparation of the ‘Lisbon consensus document’ met with EMCDDA
staff to discuss the general content of the future memorandum of understanding. 
Financial Action Task Force on Money Laundering (FATF)
The EMCDDA took part in several meetings of FATF and attended a technical
workshop on estimating drug trafficking proceeds.
Dublin Group
The Dublin Group is a flexible and informal consultative and coordinating body
that deals with world problems, regional problems and problems specific to a par-
ticular country or countries involving the illegal traffic in and the demand for nar-
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cotics. In addition to the EU Member States, the participants are Australia, Canada,
Japan, Norway and the United States. At the Dublin Group’s meeting of 29 and 30
June in Brussels, the EMCDDA was invited to present an overview of the Centre’s
activities. The Presidency invited the EMCDDA to attend future Dublin Group
meetings where specific topics related to the Centre’s activities were to be
addressed. 
Cooperation with central and east European 
countries (CEECs)
Enhanced pre-accession strategy
Under the terms of the enhanced pre-accession strategy preparing for adhesion to
the EU, the European Council of Luxembourg decided to allow the candidate
countries to participate in selected Community programmes and European agen-
cies. Priority was given to the EMCDDA and the Copenhagen-based European
Environment Agency.
During the year, the EMCDDA together with the Commission drew up the techni-
cal proposal of a technical assistance project to be funded by the Phare pro-
gramme, with the aim of preparing the candidate CEECs to take part in the activi-
ties of the Centre. This project is expected to start in February 2001.
For this purpose, a modification to the founding regulation of the EMCDDA, allow-
ing the Centre to provide technical assistance to the candidate countries and to the
countries eligible for the Phare programme, was adopted by the Council of the
European Union on 28 September. It had been approved by the European Parlia-
ment in June.
Various official visits have been paid to the EMCDDA in 2000, showing the
marked interest of the candidate countries concerning the activities of the Centre.
By the end of 2000, initial contact had been established with all candidate coun-
tries in light of their future participation in the activities of the EMCDDA, and
some of them had already formally expressed their interest in participating in the
work of the Centre (Bulgaria, Czech Republic, Hungary, Poland, Slovakia and
Slovenia).
Developing cooperation with third countries
On 28 September, the Council of the EU approved the agreement between the
European Community and the Kingdom of Norway on the participation of Norway
in the activities of the EMCDDA. The participation of Norway is expected to com-
mence in January 2001.
Some 40 delegates from third countries visited the EMCDDA headquarters in the
margins of the second high-level meeting of the ‘Coordination and cooperation
mechanism in the field of drugs between the EU, Latin America and the Caribbean’
held in Lisbon on 22 and 23 May.
On 28 February, the EMCDDA was invited to present its activities at the Mediter-
ranean Forum held under the auspices of the Portuguese Presidency in Cascais.
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Major visits to the EMCDDA, 2000
Date Visit
15 March Visit of Sergio Medinaceli, Vice-Minister of Prevention and
Rehabilitation of the Bolivian Republic
20 March Visit of HE the Ambassador of Estonia in Portugal, Mr P. Lettens
7 April Visit of the Chancellor of the Embassy of Poland in Portugal,
Ms M. Ziembinska
10 April Visit of HE the Ambassador of Slovakia in Portugal, Mr P. Hrmo
13 April Visit of the Deputy Prime Minister of Slovakia, Mr P. Casky
18 April Visit of their Royal Highnesses the then Hereditary Grand
Duke and Duchess of Luxembourg
19 May Visit of José Antonio González Fernández, Minister of Health
of the United States of Mexico 
23 May Visit of delegates participating in the second high-level meet-
ing of the EU–Latin America–Caribbean Coordination and
Cooperation Mechanism in the field of drugs 
21 June Visit of Mr P. Rakowski, Polish Ministry of Interior
21 September Visit of the International Narcotic Control Board
12 October Visit of Mr T. Deutsch, Minister of Youth and Sports, President
of the Hungarian Committee for the Coordination of Drugs
Affairs 
13 October Visit of Mr K. Tronczynski, Minister of Health of Poland 
Visit of Mr R. Muscat, Permanent Correspondent of the
Republic of Malta to the Pompidou Group
Visit of a high-level delegation from Turkey, headed by HE
the Ambassador of Turkey in Portugal 
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Major meetings attended by the EMCDDA, 2000
Date Place Event
6–10 March Vienna Commission on Narcotic Drugs, United
Nations Drugs Control Programme
30–31 March Strasbourg 45th meeting of permanent correspon-
dents of the Pompidou Group 
1–3 May Washington 27th regular meeting of CICAD
29–30 June Brussels Dublin Group meeting 
11–12 September Strasbourg 46th meeting of permanent correspon-
dents of the Pompidou Group 
11 October Sintra 47th meeting of permanent correspon-
dents of the Pompidou Group
12–13 October Sintra Ministerial Conference, Council of
Europe’s Pompidou Group
24–26 October Port of Spain 28th regular meeting of CICAD
30 October– Rhodes Interpol General Assembly
4 November
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